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To receive a kidney from a living donor is recognised as one of the optimum forms of
treatment for end-stage renal failure. In addition, the shortage of organs from cadaveric
donors has resulted in living donor numbers increasing to compensate for the shortfall.
Nevertheless, for an individual to undergo a major operation for which there is no
clinical indication requires the risk/benefit ratio to be acceptable. This thesis explores
aspects of living donor kidney transplantation to establish current practice and identify
areas for improvement. The aims of the study are:
• To establish the living donor assessment, selection criteria and follow up practice
throughout transplant units in the United Kingdom
• To measure the impact on quality of life and relationship issues for both donor
and recipient
• To ascertain if the act of donating a kidney causes short or long term physical or
psychological harm
• To determine the optimum follow-up practice for living donors
• To explore whether the standards of living donor transplantation can be
improved
The study methods included a prospective, longitudinal study utilizing quality of life
tools and specific relationship questionnaires, detailed surveys of transplant units in the
UK concerning assessment and follow-up and a retrospective study of post operative
complications. Additional work investigated insurance companies attitudes to living
donors.
Results showed that there remains variety in practice throughout the UK in procedures,
although publication of national guidelines has provided a valuable framework. This
study has demonstrated that with rigorous donor assessment only those above UK
average physical quality of life scores proceed to donation. The donors experience a
transitory decrease in quality of life following the operation and have a small risk of
major and a higher risk of minor complications. Longer term the donors are not
compromised by physical or psychological difficulties and experience an improved
relationship with the recipient. Annual follow-up is provided for those donors who wish
to attend and the majority of donors do not worry about living with one kidney.
The clinical benefits of living donor transplant for the recipient are well-recognised. The
assessment process appears to preclude those who may suffer psychological impairment
from receiving a kidney from a living donor in this study group. The recipient enjoys an
improved quality of life and relationships with both the donor and other family
members. Initial high level of concern about the donor decreases after the operation.
Careful donor and recipient selection results in successful outcome and should




1.1: The History of Transplantation
Transplantation has been described as the most stirring event of the past century in the
field of medical science. Yet the concept of removing an organ or tissue from one
person and transplanting it into another can be traced as far back as the 13th century.
Two physicians, Cosmas and Damian replaced the cancerous leg of a church sexton with
the leg of a recently deceased man, and were subsequently honoured as patron saints of
physicians and surgeons1.
Contemporary representation ofSS Cosmas and Damian painted by Durand
Copyright www.Durand .com
As is clear from the painting above, the basic concepts of vascular perfusion and
rejection which underpin modern day transplantation were not understood and it is
2
almost certain that the black limb sutured to the sexton's leg deteriorated very rapidly.
Indeed it is very unlikely that the recipient of this limb was able to sit up as portrayed in
this painting. Although many myths and legends were founded on the idea of
transplantation, it was not until the 20th century that the concept became a reality.
In 1906 in France, Alexis Carrel from Lyons was leading the field in vascular surgery.
He developed the technique of anastomosing blood vessels together to allow blood to
circulate - this heralded the possibility of using this technique with organs2. He
established a series of principles for successful vascular anastomosis that hold good
today. Subsequent work with dogs resulted in a successful autograft - transplanting the
dog's own kidney from its normal site in the retroperitoneum to the dog's neck .
Perhaps most famously he innovated the practice of removing a patch of the donor aorta
suitable for grafting onto another site - this was subsequently named the 'Carrel patch'4.
Alexis Carrel- The pioneer of
techniquesfor vascular
reconstruction and anastomosis who
was awarded the Nobel Prize in
Physiology or Medicine in 1912.




In 1933 in Russia, Yu Yu Voronoy performed the first renal transplantation in man1.
Although it was not successful he continued to treat six further patients with kidneys
from cadaveric donors, none of which worked due to lack of recognition of the effect of
warm ischaemia on the kidney5. In Paris in the early 1950s surgeons attempted a living
donor transplant on a young man who had lost his kidney due to an accident and
transplanted his mother's kidney. There was initial function, however the kidney stopped
working after a few days'. Lessons were being learnt from these experimental
procedures - future transplants would use the surgical technique practiced in Paris of
*5
transplanting into the iliac fossa
In parallel with the clinical work, investigators were studying the effect of the immune
system on the fate of transplanted tissues2. There was a pressing need to develop
techniques for repair of superficial injuries sustained from burns during battle and this
provided the impetus for early research into the immunology of transplantation.
Medawar in association with Billingham and Brent undertook a carefully structured
series of experiments based on skin grafting and were able to demonstrate
immunological rejection, accelerated rejection and acquired immunological tolerance.
Sir Peter Medawar's work describing rejection, immunological memory and tolerance
earned him the Nobel Prize in I9602.
4
Sir Peter Medawar- Arguably the Father of
Transplantation Immunology awarded the Nobel Prize
for Physiology or Medicine in 1960.
Photograph copyright of the Nobel Prize organization
http://nobelprize. org
At a similar time to Medawar's discoveries of immunological rejection, George D Snell
identified histocompatibility antigens in the mouse and this provided the basis for
antigenic identity of strains and individuals6. The Human Leucocyte Antigen (HLA)
system was discovered by Jean Dausset, for which he received the Nobel prize in 1980 ,
although the clinical significance of these findings for transplantation was not apparent
at the time2.
George D Snell
Identified the phenomenon ofspecies
and strain identity with the discovery of
histocompatibility antigens in the
mouse
5
It was Joseph Murray in Boston who successfully transplanted a kidney from one
identical twin to another at the Peter Bent Brigham Hospital in 19548. Skin grafting was
attempted prior to transplant to confirm that the twins were monozygotic, even the local
police station helped out by checking fingerprints (the media were reassured that though
the fingerprints were very similar there were differences identified)9. Murray and his
colleague Merrill used the intra-abdominal technique as devised by Kuss in Paris in
19511. The success of this transplant demonstrated that renal transplantation was a
technically feasible procedure10.
Joseph Murray
Transplanted the first kidney successfully
between identical twins at Brigham and
Womens Hospital Boston 1954. He was
awarded the Nobel Prize for Physiology or
Medicine in 1990.
Photograph copyright ofthe Nobel Prize
organization http://nobelprize. org
Up until this time the development of renal failure had been associated with a slow and
inexorable decline leading to death. Renal dialysis was in its infancy and because of the
rudimentary nature of the procedure, the high risk of infection or chemical poisoning,
dialysis itself was an extremely hazardous and ineffective treatment compared with
modern day dialysis". The importance and the benefit arising from successful renal
transplantation should not therefore be underestimated. In the United Kingdom the most
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active proponents of transplantation at the time were based in Edinburgh. Professor
Michael Woodruff was leading the development of renal transplantation in Edinburgh
and his team performed the first successful kidney transplant (between identical twins)
in the UK in Edinburgh in 1960. The donor and the recipient (with a functioning graft)
lived for 6 years and both subsequently died from stomach cancer within months of each
other1213.
Professor Sir Michael Woodruff
who performed the first successful
renal transplant in the United
Kingdom in 1960 between the
"Leith twins".
Thus, for patients with end stage renal failure with an identical twin willing to donate,
transplantation became a reality. Cleary this represented a small minority of patients.
Work began in earnest to overcome rejection, and total body irradiation was the first step
towards suppressing the immune system to stop rejecting foreign tissue1. Early
immunosuppression relied on whole body gamma-irradiation and large doses of steroids
to prevent rejection6. Such was the toxicity of these regimens that patients were required
to be incarcerated for weeks at a time in sterile units being barrier nursed with little or no
contact with the outside world. Furthermore, the risk of infection was very real and often
7
fatal in patients rendered effectively lymphopenic 2,s. Maintaining the delicate balance
between rejection and infection continues to challenge transplantation to this day.
In the 1960s Calne and Zukoski showed that 6-mercaptopurine (an anti-cancer drug) and
one of its derivatives (azathioprine) could prevent rejection in renal allografted dogs5.
These drugs were introduced to clinical practice in combination with corticosteroids in
the 1960s by Calne, Hutchings and Elion as the primary immunosuppressants for all
transplant patients and was used until the late 1970s2. In 1978 Calne introduced the
clinical use of the drug cyclosporine in Cambridge, UK5. Since that time newer
immunosuppressants such as tacrolimus, mycophenolate mofetil, monoclonal antibodies
and rapamycin have all impacted on outcome 2>14'15.
Preservation of organs for transplants was another hurdle to overcome. The first
discovery of fluid to preserve organs was almost an incidental finding by Dr Belzer in
the USA in 1966. He had stored plasma overnight and filtered out the lipid layer that had
formed, leaving clear plasma that could be used for kidney perfusion16. The Collins
solution was subsequently developed by Dr Jeffrey Collins allowing kidneys to be
17
preserved for over 12 hours
8
Professor Sir Roy Calne, who
pioneered many ofthe major advances
in immunosuppressive therapy
including 6-mercaptopurine,
azathioprine and cyclosporine A. Calne
also performed the first successful
deceased donor renal transplant in the
United Kingdom in 1962.
In order to become an established clinical therapy transplantation had to overcome many
barriers; refining the surgical technique and overcoming acute rejection and avoidance
of lethal infectious complications of immunosuppression2. The early transplants
succeeded due to a convergence of several factors - the kidney as a paired organ, an
18identical twin with chronic renal failure and an unaffected twin willing to donate .
1.2: End Stage Renal Disease
As early as the mid 1800s, the foundation for modern renal medicine was being laid. In
1861 Professor Thomas Graham from Glasgow extracted urea from urine by filtering
through a vegetable parchment coated with albumin. He called this process 'dialysis' 19.
An artificial kidney was developed by Abel in Baltimore in 1913 but never used to treat
a patient I9'19. It was not until 1943 that W J Kolff treated a patient therapeutically with
9
the invention of the rotating drum dialyser in the Netherlands, a model that was to be
20modified and used worldwide over the next few decades for selected patients" .
Unfortunately, the demand for treatment outweighed the number of dialysers available
and still many patients died from acute or chronic renal failure. Thus, before the 1970s,
therapeutic options for patients with end stage kidney failure were limited. Few dialysis
facilities had been established and kidney transplantation was in the early stages of
development as a viable option. 21.
In 1972 the Social Security amendments in the USA provided financial support for the
care of patients with end stage renal disease. By the mid 1980s, as dialysis facilities had
increased to accommodate the growing number of patients with renal failure, Medicare
18mandated evaluation of all renal patients as transplant candidates .
Here in the UK the number of people requiring renal replacement therapy also continues
to grow - the annual acceptance rate for renal replacement therapy increased from 20 per
million population (pmp) in 1982 to 101 pimp in 200222, and by the end of 2002 over
37,000 patients in the UK were being treated for end-stage kidney disease23. In 1981 the
number of patients on renal replacement therapy (including transplant) in Scotland was
469, this number increased to 3286 by 200124. Currently the estimated global dialysis
25
population is over 1.1 million and will be 2 million by 2010 .
This rise in referral of patients with renal disease may in part be explained by the ageing
population and wider criteria for acceptance onto renal replacement therapy than
10
previously22. In addition, the incidence of diabetes mellitus is rising dramatically
worldwide - in 2001 it was estimated that 150 million people had diabetes mellitus with
this increasing to 220 million by 201026. Approximately 40% of people with type II
diabetes have microalbuminuria - an independent risk factor for progression of chronic
kidney disease25.
Table 1 shows the adjusted incident rates per million population of causes of renal
failure in Scotland in 200227.
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Table 1: Adjusted incident rates per million population of causes of renal failure at
Day 1 in Scotland in 2002 - Scottish Renal Registry data
Cause of renal failure PMP %
Glomerular nephritis 15.8 15
Pyelonephritis 10.1 9
Polycystic kidney disease 6.7 6
Diabetes mellitus Type I 11.9 11
Diabetes mellitus Type II 7.1 7
Hypertension 3.2 3
Renal Vascular Disease 9.7 9
Misc/Unknown 43.5 40
Incident rates per million population ofcauses of renalfailure in Scotland at Day 1 and
percentage ofcauses ofrenalfailure- total number 548 (108.4 pmp)27
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1.3: The cost of renal failure today
1.31: Medical costs
Since the introduction of therapeutic dialysis in the 1940s there have been many
technical and medical advances. However even the most efficient dialysis regimens
today provide only 10-12% of the small-solute removal of two normally functioning
21
kidneys . It has been estimated that cardiovascular disease mortality is increased
approximately ten fold among patients with end stage renal disease28. Associated
complications of renal failure include anaemia, uraemia, hypertension, fluid retention
and left ventricular hypertrophy. Patients suffer symptoms such as tiredness, headaches,
29anorexia and weight loss" . Treatment of these symptoms has improved significantly.
Anaemia is better managed with recombinant erythropoietin therapy, new synthetic
dialysis membranes increase the overall efficiency of haemodialysis and peritoneal
dialysis equipment is constantly being refined to reduce bacterial infection risk 30.
However, mortality rates and incidence of co-morbid diseases remain high for patients
with end stage renal failure. Data from the European Renal Registry (34 countries)
shows that the 6 year survival of non-diabetic patients on dialysis (>60 years old) is 40
per cent, this is reduced to 20 per cent in diabetics. Cardiovascular mortality increases
by 10 folds in patients with end-stage renal failure31, with vascular diseases accounting
for 15 per cent of deaths in patients. Malignant disease is about three times more
common in patients on dialysis than in age- and sex-matched controls32. Long-term
complications of dialysis also include hyperparathyroidism, bone disease, hypertension.
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loss of sexual function and general fatigue and malaise21. Although dialysis is
reasonably efficient at removing small solutes e.g. potassium and urea, middle-sized
molecules such as proteins are poorly cleared and the endocrine functions of the kidney
are not replaced by dialysis33. Consequently, it is often only with a functioning
transplant that the patient will regain the ability to produce erythropoietin, adequately
clear small and middle molecules and improve blood pressure control.
An analysis of 73,103 adult transplant recipients in the United States concluded that
longer waiting time on dialysis is a significant risk factor for graft survival and patient
death. Mortality risk (defined as probability of survival at 5 years) after transplant when
waiting >48 months is 72% compared to 21% if the transplant is performed pre¬
emptively34. Further studies compared the outcome of paired donor kidneys, allocated to
patients who had end stage renal disease for more than two years compared to patients
who had end stage renal failure for less than 6 months. The graft survival in patients who
had experienced more than two years of dialysis was significantly worse at 10 years
35
(29% compared to 63% for patients who dialysed for less than 6 months) .
1.32: Social costs
Alongside the medical complications of end stage renal failure are the aspects pertaining
to day to day living. These are not separate - fatigue and malaise are the most common
complaints of patients on dialysis, along with the time spent on renal replacement
therapy and diet and fluid restrictions. Body image is also affected due to the presence
14
of dialysis access device, oedema and changes in skin appearance in some patients36.
Many patients also have fertility difficulties, with women either having conception
problems or premature birth, and impotence a common issue for males with renal
disease. Patients do manage to continue to work as they did prior to developing renal
failure, unless the job is very heavy. Some find the commitment of dialysis and
associated symptoms affects their ability to work and socialize as before, and travel and
holidays become far more difficult to organise. There are now a considerable number of
studies using different measurement tools confirming that quality of life is adversely
affected by end stage renal failure36"38, some also examine the effect of modality of
treatment, and the time on dialysis39. A study of over 17,000 dialysis patients worldwide
concluded that there was a higher risk of death and hospitalization in patients with low
quality of life scores, independent of demographic and co-morbid factors40.
Being on dialysis does not only affect the patient but also family and friends. The
commitment to treatment, restriction in activity and the on-going symptoms place a
responsibility on the close family, most notably parents of young patients and partners
within family units.
1.33: Financial costs
Three percent of the NHS budget in the UK is spent on kidney failure services41, in the
mid 1990s the estimated total cost per year for home haemodialysis was £19,300
compared with £21,000 and £22,000 for haemodialysis in a satellite unit and hospital
15
respectively42. The cost of a kidney transplant was £17,000 per patient per transplant
with a maintenance cost of £5,000 for immunosuppression per patient per year41'42. Thus
the cost-benefit of a kidney transplant compared to dialysis over a period of 9 years is
£128,000 or £14,200 per year for each year the kidney is functioning41. This data should
be used as leverage for investing in organ donation and transplantation programmes
where, unusually for the NHS, the shortage is not of money but organs.
16
1.4: Kidney Transplantation
Regrettably deceased donor rates in most countries worldwide cannot meet the demand
for transplantation. Although increasing living donor transplant rates have improved this
situation there remains a shortage of renal allografts in virtually every country in the
world.
There has been a slow but steady decline in the number of heart beating ventilated
deceased donors over the last ten years in the UK, due to fewer deaths from road traffic
accidents, better management of intra-cranial haemorrhage and a relative lack of
intensive care unit beds, thus precluding patients deemed by radiological investigation to
have a very poor/fatal prognosis from having assessment for brain stem death43.
Attempts to reverse the trend in deceased donors have been made by looking to non-
heartbeating donors as a further source for kidneys suitable for transplantation. The
number of non-heartbeating donor kidney transplants in the UK has risen from 38 in
2000 to 87 in 200444.
Countries such as the United States of America have continually increased the
percentage of living donor transplants and this would suggest that there is scope for
improvement in the living donor rates in the United Kingdom (Figure 2; Table 2). Any
17
attempt to improve numbers should not be at the detriment of either donor or recipient,
and as enthusiasm increases donor safety must always take precedence.
UK Transplant have invested in both non-heartbeating and living donor programmes
throughout the UK and the previous decline in organ donation and transplantation has
recently been reversed, as displayed in Figure 1 45.
18
Figure 1: Number of deceased donors and transplants in the UK, 1995-2004 and
patients on the transplant lists^6
NUMBER OF CADAVERIC DONORS AND TRANSPLANTS IN THE UK, 1995 - 2004
































1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Year
19
Figure 2: % Living donor of total number kidney transplants -
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Comparison of percentage of living donor transplant rates in Norway, USA and UK
1995-2004
Table 2: Total number of kidney transplants for 10 year period 1994-2004 -
Norway; USA and UK
Country Cadaveric Living Total % Living donor
Norway 1246 806 2052 39.3%
USA 85510 49321 134831 36.6%
UK 13788 3031 16819 18.0%
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1.5: The Living Donor
Large studies have shown that the long term graft survival of a kidney from a living
donor exceeds that of a deceased donor. An analysis of 93, 934 renal transplants in the
USA from 1988-1996 showed in 1995 the projected half-life for grafts from living
donors was 21.6 years compared to 13.8 years for grafts from deceased donors47. Table 3
displays European results from the Collaborative Transplant Study48. These better long-
term results from living donors are explained by the quality of the organs. Potential
living donors are extensively investigated with particular regard to renal function, and
significant co-morbidity is excluded. The kidneys come directly from a physiological
environment without the metabolic consequences of intra-crania! trauma and cerebral
death. There is minimal cold ischaemia (a median time of 1 hour) compared with a
median of 20 hours for deceased donor grafts49. From the point of view of the recipient,
there is the convenience of selecting a time that fits in with domestic and work
commitments. Furthermore, there is the ability to proceed to pre-emptive transplantation
and avoid the need for dialysis altogether, which has been proven to be the optimal
therapy for patients with end stage renal disease34. Deceased donor transplantation can
be also be pre-emptive but some clinicians feel uncomfortable with the knowledge that
this action may not be seen as fair to patients who have been on a transplant list for
many months50.
There is clear clinical evidence that, for the recipient, a living donor transplant is the best
option. The difficulty arises with the complex ethical issues surrounding the removal of
21
a healthy organ from a fit person and exposure of that individual to the risk of serious
complications. It is important to listen to the recipient who feels uncomfortable with the
possibility of a relative undergoing such an operation on their behalf. Despite this, we
still may adopt, especially with younger people when a parent is considering donation, a
paternalistic attitude of knowledge about the best option based upon clinical data.
22
Figure 3: Graft survival of first kidney transplant
Relationship
First Kidney Transplants 1985-2003
Years
CTS Collaborative Transplant Study K-15101-0805
Graft survival of kidney transplant depending on relationship, comparing kidneys from
HLA identical sibling, one haplotype matched relative and deceased donors48
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Respect for an individual's autonomy is the basic ethical concept that gives each person
the right to consent to, or refuse, treatment51. However, individuals should be given the
necessary information about the choices available and the potential consequences of
each course of action. Whilst the potential donor may be given an appropriate, detailed
description of the risks of donation, it is much less clear that all donors will listen. There
may be a tendency for some people to decide at an early stage that they wish to donate
and then to be impervious to any suggestion that they should make a more informed
decision in the light of further counselling52. The consent may be real but whether it is
53
truly informed, is questionable . It is also important to recognise that the clinical team
involved also have rights as well as responsibilities. If a fully informed donor wishes to
proceed with a course of action that involves risks of mortality or morbidity greater than
the team find acceptable, they are under no obligation to proceed.
Although the quantified risks of donating a kidney are low for this group of carefully
selected individuals, serious complications have a disastrous impact on the immediate
donor and recipient family, but also on national programmes. The death of a live liver
donor, Mike Hurewitz, in Mount Sinai Hospital in New York in 1999 caused negative
media publicity and the temporary cessation of living donor liver transplants at that
hospital34.
Living donor transplantation requires a balance. The BTS Guidelines state there should
be minimum risk to the donor with maximum benefit to the recipient55. How do we
ensure this in both the short and long term? How do we balance the complex issues of
24
autonomy and non-maleficence? This study aims to explore both the physical and
psychological effects of living donor kidney transplantation on both donor and recipient.
1.6: Aim of study
• To establish the living donor assessment, selection criteria and follow up practice
throughout transplant units in the United Kingdom
• To measure the impact on quality of life and relationship issues for both donor
and recipient
• To ascertain if the act of donating a kidney causes short or long term physical or
psychological harm
• To determine the optimum follow-up practice for living donors
• To explore whether standards of living donor transplantation can be improved
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CHAPTER 2: ASSESSMENT OF THE LIVING KIDNEY DONOR
2.1: Introduction
The act of removing a well-functioning organ from a healthy individual for the benefit
of another is a challenging concept and one that the transplant surgeon has to feel
justified in doing on both medical and moral grounds. Inherently this is in direct conflict
with the Hippocratic Oath of'primum non nocere' - first do no harm56. However, living
donor transplantation reaches beyond purely clinical factors. The surgeon has to assess
the risk/benefit balance for the individual, examining the medical, social and
psychological issues involved in each unique case57. Although the final responsibility
lies with the surgeon removing the organ, a team of health professionals assists with the
evaluation process to reach the decision whether to proceed33. Ultimately, only when
consent by the potential donor and recipient is combined with the agreement of the team
of health professionals that the balance of 'minimum risk to the donor and maximum
benefit to the recipient' has been met, will living donor transplantation proceed33.
2.1.1: Assessment criteria
The potential living kidney donor is requesting to undergo an operation that they do not
need on clinical grounds, will temporarily disable them, and will leave them with a solitary
kidney for life. The selection of individuals suitable to donate is therefore of paramount
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importance. It is somewhat surprising, therefore, that there is no worldwide consensus on
how these individuals should be selected. International studies, both in Europe and the
USA have shown substantial variability in methods of evaluating potential donors 58~53.
It is recognised in transplant units throughout the world that variation in centre practice
that some donors may be inappropriately accepted or denied64. The reasons for
inappropriate selection may be manifold but include some pressures which are outwith
purely clinical motivation. These include commercial pressure in the case of the
privately insured, pressure and inappropriate involvement from the doctor responsible
for the potential recipient and operations in some third World countries done for
commercial benefit to donor. Bia et al discussed the importance of examining current
practice patterns and defining issues that need further study in their report on the
practice of living donor assessment in the USA58. Veitch reported that the evaluation of
live donors in the UK was not based on any experimentation or clinical trial59. As living
donor transplantation continues to increase across the world, data is required to prove
that donor nephrectomy is a safe option for an individual in both the short and long term.
Although lack of consensus persists concerning who should be involved or which
investigations should be performed, most developed countries would agree a minimum of
the following58'60'65 66.
• Immunological compatibility - ABO blood grouping and lymphocytoxic
crossmatching. Incompatibility no longer excludes transplantation in some centres,
although currently the majority of transplant units in the United Kingdom would
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not proceed in these circumstances.
• General health - to exclude co-morbidities that may increase the risk of major
complications peri- and post-operatively. Risk reduction of disease transmission to
the recipient (e.g. viral or malignancy).
• Renal function - to ensure that:
a. donor has adequate renal reserve to live with a solitary kidney, and
b. the recipient receives a well-functioning transplant.
Both recipient and donor criteria must be considered when assessing the risk/benefit
balance.
2.1.2: Recipient issues
The principal issues governing the safe selection of recipients for living donor kidney
transplants are:
• Co-morbidities - The transplant operation should have a high chance of success
which clearly requires that the recipient should be medically fit for surgery and
anaesthesia and be able to tolerate common complications of renal
transplantation for example rejection, delayed graft function, hypotension or
bleeding67.
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• Primary disease - There should be an acceptably low risk of recurrence of the
primary disease such that the life expectancy of the donated kidney and the
benefit that this will bring is considered good enough to balance the risk
associated with its donation53.
• Psychosocial - The mental state and personality of the recipient should be such
that the donor can be reassured that the recipient will comply with the drug
regimen and any necessary interventions post transplantation68.
The level of balance of risk and benefit is difficult to establish and may vary between
individuals. Medical staff involved in dealing with the living donor pairing also need to
display sensitivity in helping advise a balance between the patient's wishes (autonomy)
with their own pragmatic assessment of benefit and risk (paternalism).
2.1.3: Donor issues
• General health - The donor should be suitably fit that they can withstand surgery
with a low risk of complications such that organ donation does not present an
unacceptable risk to them53.
• Renal function - The renal function of the donor should be good enough to
withstand the removal of a single kidney such that they do not develop renal
failure following donation33.
• Voluntarism to donate - The decision to donate must be given freely and without
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coercion. Particularly under United Kingdom Legislation it is unlawful for the
donor to receive payment for organ donation although there is a clause which
permits reimbursement by the Local Health Authority or Trust of reasonable
expenses which may include loss of earnings and travel69.
The objectives of the study were to establish what the donor assessment, selection
criteria and follow up practice were throughout all transplant units involved with living
donor kidney transplantation in the United Kingdom, and to enable the identification of
common practice and also highlight areas of disparity, allowing centres to examine and
evaluate procedures.
Table 3 demonstrates basic clinical investigations recommended for living donor
assessment70
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Table 3: Basic investigations for living donor assessment70
History General health: obesity, hypertension, diabetes
Cardiovascular risk: past medical history, family history,
smoking, obesity
Respiratory risk: for anaesthetic: past medical history of asthma,
etc, smoking
Risk of renal disease: family history, particularly if disease in







Immunology screen Blood group; HLA type; T & B cell FACS crossmatch
Haematology screen
Full blood count; coagulation studies
Biochemistry screen
Urea and electrolytes; Creatinine clearance;
Liver function tests; Blood glucose
Protein; blood; sugar
Culture; sensitivity & microscopy
Urinalysis
Cardiovascular
Serial blood pressure measurements; ECG




Chest x-ray; Isotope GFR; Renal ultrasound;
Angiogram/Spiral CT/MRA
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2.2: Materials and methods
All living donor transplant centres in the UK were contacted and requested to complete a
postal questionnaire at two time points - 1999 and 2002.
• Questionnaire 1 (1999) focused on clinical investigations and organisational
structure (Appendix 1).
• Questionnaire 2 (2002) explored structure, ethical issues and donor selection
(Appendix 2).
In 2000 the British Transplantation Society/Renal Association issued Living Kidney
Donor Assessment Guidelines to provide a standard for living donor transplantation
across the UK55. These guidelines comprehensively cover many aspects of the clinical
issues arising in the assessment and selection of living kidney donors and have been
enthusiastically adopted by the transplant community. Thus Questionnaire 2 was adapted
to explore the more difficult ethical issues that arise and were not addressed in the
guideline publication.
2.2.1: Questionnaire 1
In 1999 there were 35 NHS Renal Transplant Units in the United Kingdom. The results of
a telephone survey demonstrated that of the 35 centres, 30 performed live donor
transplantation. One centre performed only paediatric transplants, with adult donors being
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assessed and nephrectomy undertaken at another hospital (included in the research),
therefore the paediatric centre was excluded. One further centre assessed live donors but
had not undertaken a live donor transplant recently. Thus there were 31 centres included in
the research.
Each unit was contacted by telephone to ascertain the appropriate person or persons to
approach. The centres identified a transplant co-ordinator, nurse practitioner, physician
or surgeon. The questionnaire was sent out with a stamped addressed return envelope,
and a covering letter addressed specifically to the identified person. The forms were
marked with a unique identity number to facilitate reminder letters if required.
Respondents were assured all information would be treated in confidence and any report
would maintain anonymity.
2.2.2: Questionnaire 2
In 2002 the number of renal transplant units performing living donor transplants had
decreased to 25. All centres were contacted and an appropriate individual identified. A
structured questionnaire was sent following the same principles as Questionnaire 1.
2.2.3: Questionnaire design
A structured question survey was chosen, so that data would be comparable among
respondents71, and the majority of questions were closed, with yes/no or option answers.
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Five main rules about questionnaire design were followed72:
1. Ask questions that are easy to understand and answer.
2. Give clear instructions.
3. Adopt a format that eases analysis.
4. Allow questions to flow to maintain interest.
5. Consider overall impressions.
2.2.4: Preliminary pilot studies informing questionnaire design
Questionnaire 1 was piloted with 3 transplant co-ordinators and 3 transplant surgeons
within the local team. A specialist in research and questionnaire design was also consulted.
The feedback resulted in changes in wording of questions to improve understanding,
modifying of option answers to increase clinical choice and change in the font and
characters to improve overall impression.
Questionnaire 2 was piloted with 2 transplant co-ordinators and 3 transplant surgeons
within the local team and similar minor adaptations were made to improve overall
comprehension and to aid ease of subsequent analysis and interpretation.
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The number of personnel involved in the pilot study was restricted due to the specialised
nature of the subject and the number of qualified individuals within the UK to complete the
questionnaire.
2.3: Results
2.3.1: Questionnaire 1 (1999)
2.3.2: Response rates andpersonnel involved in completing questionnaires
Twenty-nine of the 31 questionnaires sent were returned (94%). These centres had
performed 1474 deceased donor renal transplants (98 per cent of the total for the UK and
Ireland) and 150 live donor transplants (91 per cent of the total) of which nine were
living unrelated transplants performed by seven centres. The questionnaire was
completed by the transplant coordinator responsible for living donor transplants alone in
17 centres, in consultation with a transplant surgeon in four centres, by a renal physician
in six centres, by a transplant surgeon in one centre and by a transplant surgeon and
physician together in one centre.
2.3.3: Organisation and management ofliving kidney donor assessment
The organisation of live donor assessment was examined. It was established that 19
centres already had an established protocol, four were in the process of devising a
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protocol and six had no protocol. The assessment of live donors was led by a transplant
surgeon in eight centres, renal physician in ten, transplant coordinator in one, transplant
coordinator and renal physician in two, and in eight the responsible person was not
identified. A designated transplant coordinator/nurse practitioner was employed by 20
centres to manage live donor transplantation.
2.3.4: Arrangements for donor / recipient assessment
Donor and recipient were seen separately in all centres and were also interviewed
together in 25 of the centres. Assessment by a psychiatrist or psychologist was routine
for live related donors in five centres and for unrelated donors in six centres, and was a
referral option in 13 centres for both live related and unrelated donors.
2.3.5: The intended recipient and the deceased donor waiting list
Recipients were removed from the transplant waiting list when donor assessment was
complete in four centres, on the date of operation in 17 centres, after discussion with
recipient and donor in three centres and four centres had no defined policy; there was
one non-respondent. Twenty centres did not have an agreed time period between initial
assessment and date of operation. A period of 3 months was suggested by four centres
and 6 months by five.
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2.3.6: Donor Investigations
Baseline investigations concerning the general fitness of the donor included full blood
count, serum urea, creatinine and electrolyte estimation, liver function tests, chest
radiography, electrocardiography and urinalysis; these tests were performed by all
centres. Serum levels of calcium and phosphate were measured in 28 centres, uric acid
in 20, thyroid function was determined in three, lipid profile in two and erythrocyte
sedimentation rate in one centre.
Investigations relating to diabetes, hypertension, infection screening, renal function,
renal tract anatomy and histocompatibility are summarized in Table 4. Other
investigations reported were exercise tolerance test (four centres), cervical smear for
female donors (one) and bladder ultrasonography for older male donors (one).
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Table 4 - Number of centres routinely performing specified donor
investigations




Random blood glucose 27
Fasting blood glucose 9
Blood pressure
Erect and supine blood pressure 23
Serial blood pressure 7










24-h urine for protein and 23
creatinine clearance
Isotope glomerular filtration rate 24
Renal tract anatomy
Angiography 28






Flow cytometric cross-match 21
Number of centres (29) performing investigations relating to diabetes, hypertension,
infection screening, renalfunction, renal tract anatomy and histocompatibility
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2.3.7: Hypertension
Defined values for hypertension as an exclusion criterion had been established in 12
centres, but not in the majority. Using the World Health Organization criteria for
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hypertension (mild hypertension: systolic pressure of 140-180 mmHg and/or diastolic
pressure of 90-105 mmHg) and evidence of end-organ damage such as left ventricular
failure or microalbuminuria the respondents were asked about an otherwise fit 40-year-
old man. Responses are demonstrated in Table 5.
Table 5: Donor selection and hypertension
Scenario - 40 year old man, otherwise
fit
Number of centres who would exclude
as living kidney donor
Taking one anti-hypertensive drug (no
end-organ damage)
9 centres
Mild hypertension (no medication; no end-
organ damage)
13 centres
Borderline hypertension and evidence of
end-organ damage
21 centres
Borderline hypertension and no-end-organ
damage
9 centres
Number of centres who would exclude a donor in suggested scenarios relating to
hypertension and evidence ofend organ damage
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2.3.8: Creatinine clearance
Given the scenario of a 50-year-old woman weighing 60 kg, levels of creatinine
clearance below which exclusion from kidney donation should occur were considered to
be 110 ml/min by two centres, 100 ml/min by four, 90 ml/min by four, 80 ml/min by
seven and 70 ml/min by two. No response to this question was received from ten centres.
2.3.9: Other exclusion criteria
Diabetes mellitus: A fasting blood glucose concentration of more than 6 mmol/1 was
considered an exclusion criterion for organ donation by 15 centres, a relative
contraindication by two centres and not an exclusion criterion by ten; two centres did not
respond. A family history of diabetes was considered an exclusion criterion by four
centres but not by 23, it was considered to be a relative contraindication by one centre
and one centre did not respond.
Obesity: There were no exclusion criteria for obesity in ten centres. Others excluded
donors whose body-weight exceeded their ideal body-weight by 15-20 per cent (8
centres), by 10-15 per cent (6 centres) and by less than 10 per cent (3 centres). One
centre defined a body mass index of more than 40 or weight greater than 100 kg as
exclusion criteria, while another excluded patients with a body mass index over 30.
Alcohol and smoking: A potential donor with a history of alcohol abuse would have
been excluded by 15 centres but considered by 10 and 4 did not respond. Smokers of
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more than 20 cigarettes per day would have been excluded as organ donors by 6 centres
but considered by 20, 3 did not respond.
Age: The exclusion criteria used by centres with respect to minimum and maximum
acceptable age for the donor are illustrated in Table 6.
Relationship: Child to parent donation would be considered in 25 centres, although most
considered this appropriate only in exceptional circumstances, and this relationship
would not have been considered in 4 centres.
Learning disabilities: Donors with mild learning disability would be accepted as donors
by 11 centres and excluded as donors by a further 11. Seven centres either stated that
individual assessment would be required or did not answer the question. Potential donors
with moderate learning disability were excluded by 20 centres but would be accepted by
3 while 6 did not respond.
Women of childbearing age were considered as potential donors by all centres.
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Table 6: Minimum and maximum donor age
















Minimum and maximum ages that centres recommend as limits for living donors in
29 centres
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2.4: Results: Questionnaire 2 (2002)
In 2001 the number of living kidney donor transplants increased to 358 compared to 347
in 2000 in the UK46. The 25 centres responding reflect all NHS live donor transplants
performed in 2001.
The questionnaire was sent to the living donor transplant co-ordinator in all centres and
completed by this transplant co-ordinator in 17 centres, in consultation with a surgeon in
5 centres, a physician in 2 centres and both surgeon and physician in one centre.
At the timepoint studied, 24 centres were assessing a total of 746 potential donors (range
5 - 80). One centre did not respond. Two centres performed a total of 20 laparoscopic
donor nephrectomies in 2001 and 9 centres offered this option, the remaining 16 centres
did not. Ten centres performed the donor nephrectomy and transplant simultaneously,
nine centres sequentially and 5 depending on availability of theatres. One centre did not
respond. Sixteen health boards reimbursed donor expenses and the remaining 9 received
no health board reimbursement. Donor referral option to various health professionals is
summarized in Table 7.
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Table 7: Donor referral option - 25 centres
HealthCare Professional Routine Referral option No referral
referral available option
Independent Medical Assessor 9 (related)*
Psychologist 4 9 12
Psychiatrist 3 9 13
Social Worker 4 8 13
* All unrelated donors required to be reviewed by an independent medical assessor
according to the Human Organ Transplant Act 1989




When asked which relationship pairings the centre would undertake, 5 centres had
performed grandparent to grandchild live donor transplant, 15 would consider this in the
future and 3 stated it was highly unlikely. Two centres did not respond. Twelve centres
had performed child to parent, 7 would consider it in the future and 5 stated it was
highly unlikely. One centre did not respond. No centre had performed grandchild to
grandparent, 8 would consider in the future and 17 stated it was highly unlikely. Two
centres did not respond.
2.4.2: Paired exchange and altruistic donation
Pending approval by ULTRA, 20 centres would consider paired exchange (an
incompatible pair exchanging with another pair, where the donor and recipient from
opposite pairs were compatible), 3 stated it was highly unlikely. Likewise, 16 centres
would consider altruistic donation pending legislation and 7 would not. Two centres did
not respond.
2.4.3: Further investigations
Investigations performed were reassessed in Questionnaire 2 because of publication of
living donor guidelines by the British Transplant Society/Renal Association. These
guidelines recommend the basic investigations for living donors. Centres were asked
which additional investigations are routinely performed in their centre. Results are
shown in Figure 4.
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2.4.4: Response to scenario description
Three scenarios were described based on actual local referrals and the respondents
requested to answer whether their centre would proceed with live donor transplantation
in Table 8.
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Figure 4: Additional donor investigations
Fasting blood Exercise Renal






Investigations requested on a routine basisfor all potential donors (25 centres)
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Table 8: Scenario response
Scenario 1
A 45 year old woman wishes to donate a kidney. She is married with 3 children -
age 9,11 and 15 years old. Her corrected isotope GFR is 72 mls/min, creatinine
clearance 80mls/min and differential scan shows equal kidney function. All other
investigations are satisfactory. She wishes to donate to her 15 year old son, who is
pre-dialysis.
Thirteen centres would proceed with donation, 9 centres would not and one was
undecided. One centre did not respond. When asked if this same donor wished to
donate to a friend, whom she has known since schooldays, only 6 centres would
proceed, 16 would not, two centres were undecided and one did not respond.
Scenario 2
A 40 year old woman wishes to donate to her 45 year old sister who has to travel 200
miles three times a week for haemodialysis. Due to medical history, the life
expectancy of the recipient is 2-5 years. The potential donor does not have children,
but does not rule out the possibility of a family in the future.
In this scenario, 12 centres would proceed, 10 would not and two were undecided.
One centre did not respond.
Scenario 3
A 24 year old man wishes to donate to his 55 year old diabetic father. There are no
other suitable family members, and his father has been on the transplant list for five
years. Recently the recipient has been having problems with vascular access.
Seventeen centres would proceed, 5 would not and two centres were undecided. One
centre did not respond.





This study surveyed the practice of live donor assessment by centres in the UK and
Ireland which were responsible for 98 per cent of deceased donor and 91 per cent of live
donor kidney transplants performed in 1997. Four centres did not perform living donor
transplantation and only seven performed a living unrelated transplant in 1997. This
raises the possibility that patients in some centres may not have had equal access to the
potential benefits of living related and living unrelated transplantation. Those involved
in purchasing renal healthcare for a population might reasonably ask that this modality
of treatment be available to all willing and eligible patients. In addition the investigation
of a donor and the definition of responsibility for that investigation would be considered
very important, yet, at the time, ten of 29 centres involved in live donor transplantation
did not have an agreed protocol. The absence of a protocol does not necessarily imply a
lower standard of care or evaluation, however it is generally agreed that protocols do
provide a useful structure for complex medical management and a safeguard against
inadvertent omission or incorrect procedure.
The assessment of live donors is variably led by renal transplant surgeons and
physicians, raising the question of who should be responsible for this role. It could be
argued that the responsibility for the donor ultimately lies with the surgeon and that
there is a potential conflict of interest for the renal physician, since it is the renal
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recipient who derives clinical benefit from the procedure. All unrelated donors are
required to be seen by an independent medical assessor. Although not a requirement
under transplant legislation, independent medical assessors were used by ten centres to
assess related donors. This perhaps reflects concern over the best representation of the
donors' interests and the need to have a donors' advocate. All centres interview the
donor separately from the recipient, implying recognition of the importance of
ascertaining the family dynamics and providing an opportunity for donors to raise
specific concerns which they may not wish to share with recipients. This raises the
question of whether greater involvement of psychologists would aid in clarification of
these issues.
There are no data indicating the optimal time to remove recipients from the deceased
donor transplant waiting list once living donor transplant has been agreed. The conflict
exists between the avoidance of surgery on a healthy individual who will derive no clear
direct clinical benefit and the improved graft survival rate following live donor
transplantation in comparison with deceased donor transplantation. In addition, a
deceased donor organ which is not used because the recipient is transplanted from a
living donor source can then be used to benefit another patient on the waiting list who
may not have the option of living donor transplantation. Coupled with this issue is the
question of whether it is useful to have a time lapse between initial donor assessment
and subsequent transplantation. When a policy of leaving the recipient on the deceased
donor transplant waiting list until the date of live donor transplantation is pursued in
tandem with a long time lapse between donor assessment and transplantation, this will
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inevitably reduce the availability of deceased donor organs for transplantation, since
some recipients will be offered a transplant in the interval. In the present study, the
majority of centres did not identify a rigid time period but there was a consensus that
assessment should not be hurried. Furthermore, there are individuals who have varying
degrees of commitment to donation and it may be important to consider the views of the
donor and recipient before deciding on the most appropriate time for removal of the
recipient from the transplant waiting list.
General investigations were performed by all centres but considerable variability was
observed in the methods and thoroughness of infection screening, assessment of renal
tract anatomy and renal function. The variation in practice of assessment of donors
probably reflects the availability or expertise in different imaging modalities and local
practices. No clear guidelines, based on sound clinical evidence, were available, to
indicate which factors should be considered as exclusion criteria for live organ donation.
This is reflected in the variability in response to creatinine clearance as an exclusion
criterion and the relatively high rate (10 of 29 centres) of non-responders to this
question. Similarly the WHO criteria for hypertension and the case scenario were
considered very differently by centres with some laying greater emphasis on the
presence of end organ damage and others on the presence of antihypertensive
medication. Finally the variable response to the upper limit of weight or body mass
index considered acceptable for living kidney donation was difficult to interpret and
could have been explored in more detail by applying different questions. Specifically it
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was not clear whether exclusion of obese individuals was on the basis of perceived
technical difficulty, of perioperative risk or of subsequent cardiovascular disease risk.
The ethical dilemma of organ donation and informed consent from donors with learning
difficulties is demonstrated by the low rate of acceptance (3 of 29) of donors with
moderate learning disability in the present study. In the USA, Bia et al found that 46 per
cent of centres do not have a policy regarding the use of donors with learning disabilities
and 6 per cent accepted donors with severe intellectual impairment38.
A further ethical dilemma relating to live donor transplantation arises with respect to the
age of the donor. In the UK age 18 years is the legal age for provision of informed
consent (Scotland, age 16 years)53 however, in the present study six centres set no
minimum age for organ donation. The most common age below which organ donation
would not be considered was 18 years. At the other end of the scale, older donors have
often been considered a greater operative risk and the functional results of grafts derived
from older cadaveric donors are inferior to those from younger donors74. Data from a
large series of living donors suggest that graft survival is also dependent on donor age73"
11. In the present study, 11 centres set no maximum age limit and a further six would
consider live donation from donors over 70 years of age. In spite of a move to include
older donors, only 3 per cent of all living kidney donors reported by the United Network
of Organ Sharing were over 60 years of age78.
Child to parent donation would be considered in 25 of the 29 centres, and all would
consider women of childbearing potential as potential donors. Retrospective studies have
52
suggested that donor nephrectomy does not result in any increased risk of hypertension
or hyperfiltration damage associated with subsequent pregnancy79"80.
A recent study highlighted the concern that nephrectomy may increase the subsequent
risk of developing nephropathy and advocated thorough evaluation of potential donors
for diabetes and diabetic nephropathy81, in the present study, however, 10 centres did
not consider a blood glucose concentration greater than 6 mmol/1 to be an exclusion
criterion for kidney donation. It is interesting to note that only 9 centres actually
performed a fasting blood glucose measurement the remainder relying on random blood
glucose as a screening tool.
2.5.2: Questionnaire 2
The number of potential donors assessed in 2002 (746) indicated a high level of interest
in living kidney donation. However, when comparing this to the actual number of
transplants performed, it can be estimated that approximately 50% of potential donors
did not proceed. The reasons for potential donors failing to proceed to donation include
blood group incompatibility, medical contra-indication and the recipient receiving a
cadaveric transplant82'83. With 20 centres willing to consider paired exchange, those
blood group incompatible pairings would have the opportunity to 'swap' with another
pairing. Similarly, the acceptance of marginal donors by some centres but not others
may further affect transplant numbers. As with the first study, the time at which the
recipient's name should be removed from the transplant waiting list remained variable
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throughout the UK and no consensus had been reached over this dilemma. It may be
argued that if a living donor is deemed acceptable to donate, then a deceased donor
kidney should be utilised for those who do not have a suitable live donor. Conversely,
the live donor avoids a major operation with associated risks.
The option of laparoscopic live kidney donation is rapidly increasing. A study in the
USA suggests the number of live donor transplants increases when laparoscopic
donation is offered alongside a formalized education programme84. A systemic literature
review in 2003 by Handschin concluded that laparosopic donor nephrectomy would
or
become the 'gold standard' in the near future . A lengthy discussion of the relative
merits of laparoscopic versus open donor nephrectomy is beyond the scope of this thesis,
but it is interesting that in the United States laparoscopic donation has become the
standard of care without evidence of a randomized controlled trial comparing it with
open nephrectomy. Whether patient power will exact the same change in clinical
practice remains to be seen. Length of hospital stay and improved cosmetic results
84 86
arising from laparoscopic kidney donation decrease disincentives to donation ' . In
addition, the recipient outcome in a well established laparoscopic kidney donation
programme is not compromised87"90.
The Human Organ Transplant Act 1989 allows payment of legitimate travel and loss of
earning expenses for live donors with this responsibility devolved to the discretion of the
recipient's Health Board69. There appears to be an inequality of access to this financial
assistance, and donors in regions where payments are not accessible may not proceed to
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donation due to financial reasons. This issue requires to be addressed as kidney
transplantation is the most cost-effective treatment for end stage renal disease41-91.
Currently all unrelated donors require to be assessed by an Independent Medical
Assessor for the purposes of Unrelated Live Transplant Regulatory Authority (ULTRA),
to ensure that no payment or coercion of the donor is involved. There is no requirement
for related donors to undergo such a review and it may be argued that blood relations
experience pressure from within a family. Indeed, the benefits for a spouse or partner to
donate probably outweigh those of a sibling living in another part of the country. It is
still the minority of centres who routinely request an independent review for all donors.
The acceptance of certain relationships pairings relies on the views of the transplant
centre approached. The balance of rights of the individual must be countered with the
automony of the transplant surgeon in performing this type of operation. Whilst no
centre has performed a grandchild to grandparent living donor transplant, 8 would
consider in future. This is clearly a wider acceptance criteria than the 5 centres who
state it would be very unlikely for a child to parent transplant to proceed.
The BTS/RA guidelines recommend the minimum acceptable renal function determined
by inulin clearance for a 45 year old woman should be 74 mls/min and minimum
creatinine clearance estimated by 24hour urine collection 93 mls/min. The acceptance
by 13 centres for a woman with renal function below these limits for her son, and only 6
centres for her friend indicates the influence that relationship pairings have on the
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decision making process. It may be argued that the rights of the donor should be
respected and if she is deemed to be medically suitable the relationship with the
recipient is irrelevant. However, in one of the other scenarios the life expectancy of the
recipient, which may exclude his/her acceptance onto the cadaveric list due to the
shortage of kidneys available for transplantation, did not prove to be a contra-indication
to living donation in 10 centres. It may be suggested that by providing a personal
'resource' will compromise others waiting on the transplant list. The variation in
acceptance demonstrates the difficult ethical decisions requiring to made by transplant
teams.
2.6: Conclusion
The British Transplantation Society and the Renal Association established a working
party in 1999 to develop a national protocol to provide a consistent standard of care and
assessment of live donors throughout the UK and these guidelines were published in
200035. However our second study has shown that there remains a variation in practice
throughout the UK in selection of living kidney donors. Although many of the clinical
aspects of assessment and selection were addressed the more challenging ethical issues
require further debate and agreement. The acceptance of marginal donors depends on the
individual centres, as does the relationship criteria. Some centres refer a donor who has
been deemed unsuitable to other centres and this practice is likely to increase with more
patient autonomy. Department of Health guidelines aim to enable patients the right to
choose treatment options and the hospital that they receive treatment from by December
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922005 . The option of laparoscopic donation is not available to all donors, and since this
has the potential to increase the number of living donor transplants a referral option
should be offered to those wishing this type of surgery. Overcoming barriers such as
blood group incompatibility and positive lymphocytotoxic crossmatching with 'paired
exchange' requires the forthcoming changes in the law following which the majority of
centres would consider this option.
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CHAPTER 3: QUALITY OF LIFE
3.1: Introduction
In 1946 the World Health Organisation defined health as 'a state of complete physical,
mental and social wellbeing, and not merely the absence of disease and infirmity'93 and
subsequently tools were developed to measure quality of life. Within the clinical field,
the aim of such measurements has been to calculate changes in physical, functional,
mental and social health in order to evaluate the human and financial costs and benefits
of new programmes and interventions94,95. By the end of the 1990s there were over 800
instruments to measure health-related quality of life96. In general there are two types of
quality of life assessment instruments - generic and disease-specific questionnaires. One
of the most well known generic health profiles is the SF-36, which was developed from
the Medical Outcomes Study in America96. Tools such as this, and the World Health
Organisation Quality of Life assessment instrument, provide a comparative scoring
system for a range of individuals, cross culturally, and for a range of health conditions
(including well) 97'98. Disease specific questionnaires such as the end-stage renal disease
questionnaire are only valuable when comparing treatment options for a select group of
patients with identical disease processes99.
Health economists usually prefer to use health indices to carry out cost-benefit analysis.
A health indices is calculated by a single index with a range from 0 to 1.0 (0 being death
and 1.0 being quality of life achieved with perfect health). A health indices score can
then be multiplied with life expectancy to provide a QALY (Quality-adjusted Life
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Years). This does not measure quality of life but gives a value to the outcome of
treatment in terms of years spent in an improved health state96.
The rapid development of transplantation over the past half century has resulted in major
advances in the clinical field, with more promised in the future100. It is important that the
full range of cost and benefits to the individual recipient, his or her family and society in
general are also considered 101. In the case of living donation, the cost and benefit to the
donor must also be measured. Many studies examining quality of life issues in living
donor kidney transplantation have been retrospective, or have focused on cohorts of
102either donors or recipients in isolation as described in the examples shown in Table 9
114. In the United States, one study revealed that live kidney donors have similar or
higher scores in all quality of life domains compared with the healthy US population and
this observation was independent of the time since donation 109. Another European study
demonstrated that recipients of both living donor and cadaveric transplants had mean
quality of life scores within one standard deviation of the norm for healthy
individuals115. Although such studies are useful, there is a lack of objective longitudinal
data examining the relationship dynamics and quality of life of both donor and recipient
as a pair through the process of living kidney donation and transplantation.
Relationships between donor, recipient and other family members provide a complex
challenge. Feelings of guilt have more prominence in the recipients of transplants
originating from living donors compared with cadaveric donors115. Individuals donating
a kidney were less likely to say they would donate again (if it were possible) if they were
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donating to a person who was not a close blood relative or if the recipient of their kidney
had died in the first year after transplantation109. Many of the quality of life studies have
been performed in Europe, the USA and Australia, where payment for organs are illegal.
A study by Zargooshi in Iran of 300 living kidney donor 'vendors' reported a negative
effect on the majority of donors, with 85% saying they would definitely not vend again
and the donors had significantly lower quality of life scores post donation compared to
controls114
The lack of good quality and objective data concerning quality of life outcomes for
living kidney donors and transplant recipients means that it is difficult for health care
professionals to provide advice to individuals considering kidney donation other than in
the context of clinical measures such as graft survival and operative risk. The present
study was designed specifically to investigate the effect of donating or receiving a
kidney among donor and recipient pairings on their quality of life and relationship
dynamics over time.
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C Cabrer; Spain 22 Donor - retrospective
Cetingok M; USA 293 Recipient - prospective
Christenson; USA 95 Recipient - prospective
de Graaf Olson W; USA 118 Donor - retrospective
Giessing M; Germany 106 Donor - retrospective
Griva K; UK 347 Recipient - retrospective
Isotoni S; Japan 69 Donor- retrospective
Johnson EM; USA 524 Donor - retrospective
Luk W; Hong Kong 31 Recipient - retrospective
Russell JD; Canada 27 Recipient - prospective
Siegal B; USA 3676 Recipient - retrospective
Smith GC; Australia 48 Donor - prospective
Zargooshi J; Iran 307 Donor - retrospective
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3.1.2: Measuring Quality of Life-the World Health Organisation Group
A common definition for quality of life has yet to be achieved "6. As it is a subjective
concept, and tools developed have to be used in a variety of cross cultural settings, the
emphasis has to be on what is important for each individual117. The World Health
Organisation Quality of Life group (WHOQOL) define quality of life as 'an individual's
perceptions of their position in life in the context of the culture and value systems in
I'iii* •• • 118which they live and in relation to their goals, expectations, standards and concerns'
The subsequent development of the World Health Organisation Quality of Life
Assessment Questionnaire (WHOQOL -100) was simultaneously developed in 15
118international field centres so the questionnaire would be applicable cross-culturally .
Following the 15 centre pilot 100 items were selected for inclusion in the assessment.
(Table 10)
The WHOQOL Bref is a shortened form of the WHOQOL 100 and discriminates
between 'well' and 'ill' subjects118. This was felt to be particularly important as many
quality of life questionnaires are designed to assess the impact of illness on a population.
As this study compared 'healthy' donors and patients with end-stage renal failure the
WHOQOL Bref was selected. Data were also available to compare an age-matched well
population in the United Kingdom and worldwide119. Twenty-six questions produce
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scores for four domains; physical, psychological, social and environmental related to
quality of life.
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Table 10: WHOQOL-BREF domains of quality of life
Domain Facets incorporated within domains




Activities of daily living
Dependence on medicinal substances and
medical aids
Work capacity
2 Psychological Positive feeling
Thinking, learning, memory and
concentration
Self-esteem
Bodily image and appearance
Negative feelings
Spirituality/religion/personal beliefs
Social relationships Personal relationships
Social support
Sexual activity
Environment Freedom, physical safety and security
Flome environment
Financial resources
Health and social care: accessibility and
quality
Opportunities for acquiring new
information and skills
Participation in and opportunities for




The 24 facets (grouped into 4 domains) regarded by the World Health Organisation
Quality of Life group as important in assessing overall quality of life and general
health'18
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3.2: Methods and materials
This prospective, longitudinal study was undertaken between January 2000 and January
2004 in the transplant units of the Royal Infirmary, Edinburgh and Addenbrooke's
Hospital, Cambridge. Both centres had similar policies regarding donor and recipient
selection, pre-operative assessment and perioperative care. During the course of the
study all donor nephrectomies were performed using an open technique with or without
resection of the twelfth rib. Only adult subjects (>18years) were invited to participate as
agreed with the local ethical approval committees. Both donor and recipient were asked
to complete two questionnaires each at three time points: before; six weeks after and one
year after the live donor transplant. The questionnaires included the World Health
Organisation Quality of Life Bref (WHOQOL) and an additional questionnaire
examining relationship issues and concerns related to the procedure (Appendix 4-6).
The additional questionnaires were designed using a 10cm linear-analogue scale with a
member of the WHOQOL group (MJP) assisting in the development of the questions.
The respondents were asked to state their response from minimum to maximum views
on the scale. The recipients completed the same questionnaire at the same time points.
The donor pre and post-operative questionnaire differed to encompass further social and
economic issues experienced post donation.
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The donor and recipient pairs were asked to complete the questionnaire separately, to
avoid conflict of responses. The majority were completed during routine clinic visits,
although due to geographical limitations a number were posted and returned. The
questionnaires were numerically coded and anonymous, though demographic details
were requested.
3.2.1: Statistical analysis
The WHOQOL-BREF produces a quality of life profile deriving the four domain
170
scores . Higher scores denote higher quality of life. Data is analysed with an SPSS
syntax file that recodes data and computes domain scores. Relationship data were
transformed and analysed with SPSS, using Mann Witney or Kruskal-Wallis H test as
appropriate. Data are presented as boxplots, displaying the median score, interquartile




From January 2000 to December 2002 52 donor and recipient pairs consented to
participate, 3 pairs declined. Twenty-three of the pairs were parent to adult child, 11
siblings, 16 spousal and 2 other non-related. Forty donors and 35 recipients completed
the questionnaires at all 3 time points. Individuals who did not complete questionnaires
at all time points were excluded from analysis. Treatment for renal failure for the 35
recipients included 13 undergoing haemodialysis; 14 peritoneal dialysis and 8 were
transplanted before renal replacement therapy was necessary. All donors underwent
open nephrectomy in this selected group. The mean age for the donors was 49 yrs
(range 24-71 yrs), the recipients' mean age 37 yrs (range 19-54 yrs). Twenty-Five donors
were female and 15 donors male, 17 recipients were female and 18 male. One recipient
died within one year of transplant and one recipient received two live donor transplants
over the time period, the first having failed within one year. No donor suffered a major
peri-operative complication.
3.3.2: Quality oflife assessment
The WHOQOL scores are reported in the four domains - physical, psychological, social
and environmental. The median physical scores for donors are summarised in Figure 5
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and further domain scores in Table 11. Recipients median physical score are
demonstrated in Figure 6 and further domain scores in Table 12.
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WHOQOL physical domain scores for adult donors of kidneys before, six weeks and 1
year after kidney donation. The boxplot displays the median score (middle line), the
interquartile range and error bar range. The broken lines represent the median
physical domain score an age and sex matched healthy UK and global population
There was a significant reduction in physical domain scores 6 weeks after donation
(f2= 17.2;df=2p<0.0001 Kruskal-Wallis H test) with scores returning to pre donation
levels by one year.
Before 6 wks after 1 year after
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Figure 6: Recipient physical quality of life domain
UK well
Global well
Before 6 wks after 1 year after
WHOQOL physical domain scores for adult recipients of kidneys before, six weeks and
1 year after living donor kidney transplantation. The boxplot displays the median score
(middle line), the interquartile range and error bar range. The broken lines represent
the median physical domain score an age and sex matched healthy UK and global
population. There was a significant increase in physical domain scores 6 weeks after
transplantation = 26.6;;df=2p<0.0001 Kruskal-Wallis Htest.)
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Table 12:WHOQOL recipient physical, psychological, social and environmental
domain scores
QOL domain Before 6 wks 1 year UK well World well
n=35 n= 35 n=35 n=245 n=4472
Physical 11.4 14.9 16.0 16.4 15.4
(9.7-13.7) (13.1-17.1) (13.7-18.3) (14.1-18.7) (12.6-18.2)
15.3 16.0 16.0 14.6 14.8
Psychological (12.7-16.0) (14.7-16.7) (15.3-16.7) (12.0-17.5) (12.1-17.5)
16.0 16.0 16.0 15.4 14.9
Social (9.3-20.0) (8.00-20.0) (10.6-20.0) (11.7-18.0) (11.0-17.2)
16.0 16.5 16.0 14.7 14.1
Environment (8.5-10.0) (10.0-19.5) (9.0-19.5) (11.4-16.7) (11.4-16.8)
WHOQOL physical, psychological, social and environmental domain scoresfor adult
recipients ofkidneys usedfor living-donor kidney transplantation, compared to UK and
global healthy norms.
72
































Therewasasignificantreductioiphys ldoma nscores6w kaftdon tion(=17.2;f=2p<0.0001Krusk l-W llisHtes )wi hcor sr turn g
topredonationlevelsbyny ar.Thwsignificantincre sphysic ldom nsc res6w kaft rtran planta ion(x=26.6;;df=2p<0.0001 Kruskal-WallisHtest.)
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Within the physical domain the median score for the donor was significantly higher than
the UK normative value for a healthy person (p<0.001). Six weeks after donation, the
physical domain scores of donors reduced to normative levels however improved again
at one year, although did not reach pre-donation levels. By contrast the median score for
the recipient before transplantation was significantly lower than the UK normative value
for a well person (11.4 pre-transplant vs 16.4 UK norm p<0.01). The physical domain
quality of life measurement for the recipient significantly improved by 6 weeks and
continued to improve such that by one year following living kidney transplantation it
was not significantly different from the UK normative value for a well person.
Donor psychological domain scores before kidney donation were significantly greater
than UK normative values for a well person (p<0.012). Although the donor
psychological domain median decreased six weeks post donation, this score remained
significantly higher than the UK population normative value (p<0.001). The recipient
psychological domain scores before transplant were not significantly different from the
UK normative value. However, following transplantation the psychological domain
scores increased such that they were significantly higher than UK normative values at
six weeks and one year (p<0.01). There was no significant difference between the donor
and recipient psychological domain scores one year after kidney donation or
transplantation respectively.
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There were no significant changes in either the social or environmental domain scores of
the donor or recipient groups before and after kidney donation or transplantation.
Individual cases to highlight within these results include the two donor and recipient
pairs (Pair A where the recipient died within one year of transplant and Pair B where the
graft failed due to rejection after eight months). All other transplants were successful
and functioning at one year.
Pair A donor reported no difference in the physical, social or environmental domains,
with a significantly lower psychological score at one year. The recipient reported an
improvement in both physical and psychological domains at six weeks, sadly he was
diagnosed with a malignancy six months post transplant and died shortly thereafter. Pair
B's results are demonstrated in Table 13. Interestingly the recipient psychological
domain returned to pre-transplant levels when the graft has failed and there was a
decrease in both social and environmental scores, although the physical score did not
return to pre-transplant levels.
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Table 13: Pair B donor and recipient median scores
Donor Recipient
QOL domain Before 6 wks 1 year Before 6 wks 1 year
Physical 18.3 17.1 16 6.3 16 9.7
Psychological 17.3 16.8 14.0 9.3 15.3 9.3
Social 18.7 16 16 14.7 17.3 13.3
Environment 17.5 17 14.5 11.5 13.1 9.1
Quality of life scoresfor Pair B (graftfailed at 8 months)
3.3.3: Relationship and social issues
The impact of living donor transplantation on the relationship of the pairing and family
member and friends was addressed. The participants were asked to score on a linear
analogue scale if the issue of live kidney donation had improved their relationship. The
scale measured 10cm (0: not at all - 10: and extreme amount). The donor and recipient
were also asked if the issue of live kidney donation had an adverse effect on relationship
using the same scale. Both donor and recipient reported a significant improvement in
their mutual relationship (Figures 8 & 9). When asked if the issue of live kidney
donation had any adverse effect on their relationship, the donor median score was 0.8
pre donation, 1.7 six weeks post and 2.2 one year post. The recipient median score was
lower: 0.6 pre transplant, 0.6 six weeks after and 0.7 one year later.
The recipients were asked to score their level of concern about the donor on the same
10cm scale (Figure 10). Initially the recipients expressed a high level of concern
(median score 8.8) reducing at six weeks to 5.4. The donor was asked about their level
of concern about their remaining kidney (Figure 11). Consistently the donors did not
worry about their remaining kidney - 0.8 before the operation and six weeks after and
increasing to 1.0 one year after. Post-operatively, when asked about scar discomfort
experienced the median donor score was 2.0 at six weeks and 2.4 at one year. When
asked, if it were possible, would they donate a kidney again, the donor median score was
8.9 at six weeks and 9.3 at one year.
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Figure 8: Donor relationship with recipient
PRE 6 WEEKS 1 YEAR
Donor relationship with recipient scores before, six weeks and 1 year after living donor
kidney transplantation. The boxplot displays the median score (middle line), the
interquartile range and error bar range. Donors report significant improvement in their
relationship with the recipient following kidney donation (p< 0.009)
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Figure 9
Recipient relationship with donor
— 1 r—
PRE 6 WEEKS 1 YEAR
Recipient relationship with donor scores before, six weeks and 1 year after living donor
kidney transplantation. The boxplot displays the median score (middle line), the
interquartile range and error bar range. Recipients report significant improvement in
their relationship with the donorfollowing kidney transplantation (p<0.05)
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Figure 10
Donor relationship with family members
PRE 6 WEEKS 1 YEAR
n/s
Donor relationship with family members scores before, six weeks and 1 year after living
donor kidney transplantation. The boxplot displays the median score (middle line), the
interquartile range and error bar range. Donors report no significant change in
relationship withfamily members.
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Figure 11: Recipient relationship with family members
sjjsilltsHBB
PRE 6 WEEKS 1 YEAR
Recipient relationships with family members scores before, six weeks and 1 year after
living donor kidney transplantation. The boxplot displays the median score (middle
line), the interquartile range and error bar range. Recipients report significant
improvement in relationships with otherfamily members (p<0.004).
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Figure 12: Recipients concerns about the donor
—X 1
PRE 6 WEEKS 1 YEAR
Recipient concerns about the welfare of the donor before, six weeks and 1 year after
living donor kidney transplantation. The boxplot displays the median score (middle
line), the interquartile range and error bar range. Recipients report significant
reduction in concerns about the donor after living donor transplant(p<0.0001).
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Figure 13: Donor concern about remaining kidney
PRE 6 WEEKS 1 YEAR
Donor concerns about their remaining kidney before, six weeks and 1 year after living
donor kidney transplantation. The boxplot displays the median score (middle line), the
interquartile range and error bar range. Donors do not have significant change in
concerns about remaining kidney (n/s).
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3.4: Discussion
This prospective, longitudinal study demonstrated that living donor kidney
transplantation does not adversely affect the longer term physical, psychological and
social wellbeing of donors and substantially improves many aspects of the lives of
recipients. The intense medical evaluation of potential living kidney donors results in the
selection of only healthy, motivated individuals. In addition, all live kidney donors are
encouraged to achieve a high level of fitness prior to donation. In the light of this it is
perhaps not surprising that the physical domain score for donors before operation is
above the national norm, confirming results of previous studies105'106'109. Likewise for
the recipient, the physical improvement following transplantation confirms the benefit of
this form of treatment28'121"123.
The donors achieve a higher than normal psychological score pre-donation, decreasing
at six weeks and one year, although remain at a level above the healthy population. It is
possible that the selection of motivated individuals, coupled with the reassurance
afforded by completion of the assessment process and the knowledge that they are fit to
proceed, improves psychological well-being before donation. Similarly, for the recipient
the knowledge that a transplant is imminent, may increase a sense of psychological well-
being, in spite of the observed concerns that the recipient has for the safety of the donor.
No significant change in the social and environmental domain scores of either donor or
recipient were observed. This is reassuring information for future donors that no adverse
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effect is caused by donation. It was anticipated that for the recipient, freedom from
dialysis might have resulted in improved social and environmental interaction. The lack
of change may reflect the fact that a number of transplants were 'pre-emptive' (that is
undertaken before dialysis was instituted) or the intensity of the follow up after
transplantation. Benefits in social and environmental domains may become more
apparent in the longer term, when the recipient does not require such intense follow-up.
Both the donor and recipient are informed in detail about the risks and benefits of living
donor transplantation124, with great emphasis on the risks to the donor undergoing a
major operation. Thus recipient concerns about the donor are high before surgery,
decreasing in response to successful outcome and donor recovery. The donors continue
to have a low level of concern about living with a solitary kidney. The emphasis during
assessment that donation will only proceed with minimum risk to the donor and
maximum benefit to the recipient 124 may partly reassure donors, alongside the life-long
follow-up commitment of the transplant team.
The impact of living kidney donation does not appear to have adverse effects on
relationships either between donor and recipient or with other family members. The
rigorous evaluation process may preclude pairs with the potential for family conflict.
Donors consider that the act of donation improves relationships with the recipient and to
a lesser extent with family and friends, whose support is vital in the post-operative
period.
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This study has demonstrated that living donor kidney transplantation does not adversely
affect the lives of donors and substantially improves many aspects of the lives of
recipients. Careful donor selection allows those with a higher than normal physical
quality of life to donate without impairing their physical or psychological status. As a
group, the issue of donation and transplantation does not have an adverse effect on
relationships. The majority of living donors would donate again, providing reassuring
information for potential donors.
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CHAPTER 4: POST OPERATIVE COMPLICATIONS
4.1: Introduction
For the recipient of a living donor kidney transplant the clinical benefits are well
recognized. As has been demonstrated transplantation versus dialysis provides
improvement in quality of life, extends life expectancy and reduces co-morbid
12131125 . • .conditions . ' Given that living donation is the only procedure where there is no
obvious medical benefit to the donor it is incumbent on the medical profession to ensure
that this is a safe procedure in which all possible risks are minimized. It is therefore
important that the clinical implications of donating a kidney are adequately researched
and monitored.
Various worldwide studies have addressed these issues, with more recent comparisons
85 87 126 127of the complications of laparoscopic versus open nephrectomy ' ' ' . The reporting
of post-operative complication rates varies widely, possibly due to under reporting in
large data registries compared to detailed casenote review. Many case series of living
kidney donors are published on the premise that this is a safe and effective procedure
and while this may be true the very premise that it is safe may introduce an inherent bias
leading to a relative under-reporting of complications. Coupled with this is use of
publications as advertisements for commercially driven medical care delivery.
Publication of a large series with no mortality and low morbidity is a powerful
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advertisement to both insurers and clients in countries that operate on a health insurance
cost recovery basis rather than a nationally funded health care system such as our own.
Nevertheless, large series based on registry data do report low death rates following
128
living kidney donation and the reported death rates range from 0.03% - 0.06% . In
these series the reported causes of death are predominantly pulmonary embolus and
1 9 8" 1 9Q • •
cardiac events ' . In a summary of perioperative complication rates for living donor
nephrectomy for a large number of single centre studies the mean overall complication
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rate was 32% and the major peri-operative complication rate was 4.4% . Minor
complications have been estimated between 8- 48% with 1.8% patients suffering from
major complications128. The spectrum of complications reported in the literature
following living kidney donation is broad with some complications being what would be
considered general complications of anaesthesia and the perioperative period and other
128' 131132
clearly being related specifically to the procedure of living kidney donation • '
Rigorous donor assessment ensures that only healthy individuals with two well-
functioning kidneys proceed to donation, and previous studies have shown kidney
donors have an increased life expectancy when compared with an age-matched
population133 . Table 14 summarises a study looking at morbidity and mortality after
living kidney donation in the USA from 1999-2001, comparing laparoscopic and open
nephrectomies132. Rates for reoperation, complications and readmissions were slightly
higher for laparoscopic nephrectomy, however <1.3% overall for both types of surgery.
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The purpose of this study was to examine the precise nature and quantity of short term
complications following living kidney donation in two UK centres with similar practice
for living kidney donation.
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Bleeding 0.15 0.18 0.45
Bowel obstruction 0.05 0.27 0.1
Bowel injury - 0.1 0.14




Pneumothorax 0.09 0.05 -
Prolonged ileus - 0.05 0.06
Rhabdomyolysis - 0.09 0.13
Readmission rate 0.6% 1.6%
Retrotrospective survey of live donor nephrectomy complications in 171 transplant units
in the USA (73% response rate)
90
4.2: Methods and materials
Peri-operative adverse events were documented in 95 consecutive live kidney donors
undergoing open nephrectomy in Addenbrooke's Hospital Cambridge (37 donors) and
the Royal Infirmary of Edinburgh (58 donors) between 1997 and 2001. Both centres
followed similar protocols for the evaluation of potential live kidney donors, involving
rigorous assessment of general health and kidney function. A significant difference in
the management of donors was that Cambridge routinely prescribed prophylactic
antibiotics at time of anaesthetic induction while Edinburgh did not. This allowed
comparison of the effect of antibiotic prophylaxis on the frequency of infective
complications in donors. In addition, the majority of Edinburgh donors received epidural
pain control, whilst Cambridge donors did not. An open approach with or without
resection of the 12th rib was used for all procedures in both centres.
Donor complications were defined and recorded in a standardised format using a
proforma specifically designed for this study and based on detailed case note review.
Wound infection criteria followed Scottish Intercollegiate Guideline Network
recommendations'34. The influence on the complications of age, gender, body mass
index, smoking status and transplant centre was assessed.
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4.2.1: Statistical A nalysis
Results are presented as actual numbers, percentages or medians and ranges as
appropriate. Complication rates between different groups were compared using the
Pearson 2-sided Chi squared test. Length of stay in patients related to the presence or
absence of peri-operative complications was compared using the Mann Whitney-U test.
Statistical analysis was performed using SPSS version 11 for Windows.
4.3: Results
4.3.1: Donor characteristics
Of the 95 donors studied, 45 were men and 50 women. The recipients of these kidneys
were 57 men and 38 women. Seventy-four of the transplants were performed between
related pairings and 21 were unrelated. Of the 74 related, 13 shared both haplotypes; 53
shared one haplotype and 8 did not share a haplotype. The median age at time of
donation was 46 years (range 24 - 65 years). A left nephrectomy was performed in 58
cases, with 37 patients undergoing a right nephrectomy. Twenty-six (27 per cent) of
patients were smokers at time of donation, 3 (3 per cent) had given up smoking within
six months of the surgery and the remaining 66 (70 per cent) were non-smokers. The
Body Mass Index was calculated in 79 of the 95 donors, of these 11(14 per cent) were
calculated to have a BMI >30.
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4.3.2: Peri-operative complications
All peri-operative complications were reported, however minor. Sixty-four patients (67
per cent) had one or more peri-operative complication. These are summarised in Table
15. Two major complications were noted; one peri-operative haemorrhage and one post¬
operative haemorrhage, both requiring red cell concentrate transfusions. No correlation
was found between conditional variables such as smoking habit, body mass index>30,
gender and age and complication rates. There were no deaths in the study population.
Post-operative pyrexia was recorded in the majority of patients within 48 hours of
surgery (Figure 13). Seventy (74 per cent) of patients recorded a peak temperature
>37.5°C, with 47 (50 per cent) recording a peak temperature >38.0°C. Within the latter
group, only 25 (53 per cent) had a proven infection. Infective complications were found
in 11 of 37 (30 per cent) donors from Cambridge compared with 27 of 58 (47 per cent)
donors in Edinburgh (Chi squared=2.66, df=l, p=0.1).
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Table 15: Peri-Operative Complications
Peri-operative Complications Number Per cent of Donors
Atelectasis 19 20
Chest infection 18 19
Urinary tract infection 12 13
Wound infection (superficial) 6 6
Wound infection (deep) 4 4
Wound dressing allergy/cellulitis 8 8
Peritoneum breached 7 7
Pneumothorax (no intervention required) 5 5
Epidural leak 2 2
Leg paraesthesia 2 2
Bleeding 2 2
Wound dehiscence 1 1
Pleural effusion 1 1
Sub-phrenic collection 1 1
Epidural catheter infection 1 1
Colitis 1 1
Cannula site infection 1 1
Wound haematoma 1 1
Peri-operative complicationsfollowing open nephrectomy in 95 donors














Pre-op Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
Temperature changes before and following open donor nephrectomy. The boxplot
displays the median score (middle line), the interquartile range and error bar range,
with outliers.
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Constipation requiring medication occurred in 44 of 58 donors (76 per cent) who
received epidural analgesia postoperatively compared with 22 of 37 donors (59 per cent)
who received a combination of opiate and non-steroidal anti-inflammatory analgesia
(Chi squared=2.9, df=l, p=0.09. No other centre differences were noted.
The median hospital stay was 5 days (range 3-8) for donors without post-operative
complications and 6 days (range 3-12) for those with complications (p<0.01).
4.4: Discussion
Open nephrectomy for live kidney donation is associated with a low incidence of major
complications however minor complications were significantly more common in the
present study than previously reported 128'131 This high complication rate may be
explained by the detailed reporting of all aspects of post-operative care, including
dressing allergies and asymptomatic atelectasis in this study.
The high rate of post operative pyrexia presumably reflects the metabolic response to
surgery since microbiological cultures were positive in only a minority of patients with
elevated body temperature. Postoperative pyrexia has been well recognised as a
consequence of major surgery135"137 but not previously described in the context of living
kidney donation. It has previously been shown that the presence of epidural analgesia
does not influence the development of post operative pyrexia and this was also the case
in this study138.
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There was no significant difference in the rates of proven infective complications
between patients treated in Edinburgh and Cambridge in the absence and presence of
prophylactic antibiotics respectively. This was not a primary outcome objective of this
study and as such the study was underpowered to detect a difference in infection rates.
While non-significant there was a trend for patients receiving antibiotic prophylaxis to
have lower rates of infective complications and this unresolved question requires further
study. Post-operative pyrexia is a common event occurring in the majority of donors
and in the absence of positive microbiological cultures does not warrant intervention.
The high rate of constipation in both centres did not appear to be significantly related to
the type of post-operative analgesia.
The lack of correlation between smoking habit, BMI and age and perioperative
complications could be attributed to the relatively small sample size but equally it may
serve to demonstrate that the donor selection process eliminates the negative impact of
adverse variables by excluding unhealthy individuals.
Potential live donors should be made aware of a relatively high incidence of minor
complications in the early period following donor nephrectomy. Equally potential
donors can be reassured that the incidence of serious complications is low. Data on the
intermediate and long term outcome of live kidney donors in the UK is required to
provide comprehensive information and supports the recommendation of the British
Transplantation and Renal Society Guidelines that live kidney donors should undergo
formal long term follow up.
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CHAPTER 5: INSURANCE ISSUES IN LIVING KIDNEY DONATION
5.1: Introduction
The quantification of risk by insurance companies will affect assessment of kidney
donors as potential customers. The long-term financial implications of donation have
been documented as an area of concern for both donors and recipients'39. The majority
of studies into insurance provision in this patient group are from the United States of
America and have concluded that donors experienced no difficulties in gaining either
life or medical insurance after donation. In 1986, Smith et al. found that 4.2% and 2.3%
of donors admitted problems in obtaining life and health insurance respectively and that
98.3% noted no increase in premiums139. The aim of this study was to ascertain the
perspective of UK insurance companies to provision of insurance to live kidney donors
since there are major differences in the organisation of health care in the UK and USA.
This study formed part of a Special Studies Module for Sarah Clarke, 4th Year Medical
Student at the University of Edinburgh.
5.2: Methods and materials
WHICH (consumer guide) and customer directories were used to determine the major
life and health insurance providers in the UK. Thirty-two Life and 17 Medical Insurance
companies were included. The Association of British Insurers was contacted to verify
the number of people in the UK who have life insurance.
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Separate questionnaires were designed for both health and life insurance providers and
an appendix (detailing the assessment procedure and long-term physical consequences
for donors) was attached. The Life Insurance questionnaire examined specific issues
concerning cover should a donor die during or after surgery, and the acceptance of new
customers pre and post donation. The Health Insurance questionnaire focussed on




Of the 32 Life Insurance companies approached 14 replies were received (44%). These
14 companies insure approximately 6.5 million customers. Approximately 8.2 million
people in the UK hold a life insurance policy and therefore results were obtained from
companies supplying 79% of UK life insurance.
When questioned regarding their policy if an existing customer should die during kidney
donation, 13/14 stated that they would pay the agreed life insurance sum. One company
did not provide an answer as they had no experience of the situation and are currently
deciding their position for future reference. No companies required to be informed by a
customer of their intention to donate. Furthermore, 14/14 would accept new customers
after previous kidney donation and would not charge an increased premium. When
questioned if the time since donation was a factor taken into consideration when
assessing new customers, 12/14 stated that it was. Insurers stated that for new customers
the time since donation ceased to be relevant after 3 months (2/14), 6 months (7/14), 2
years (2/14) and one did not specify a time but considers customers "once full recovery
is established". In addition, 3/14 stated that the donor must "demonstrate a full recovery
and be able to undertake all normal activities". If a new customer were considering
donation 3/14 would only accept the individual after donation and full recovery.
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5.3.2: Health Insurance
Of the 17 Health insurance companies approached 7 replies were received (41%). The
questionnaire was not completed by 1/7, as they "do not market new business". Of the
remaining six companies; 3/6 cover existing customers for kidney donation and of these,
one covers donor investigation costs, donor operation, hospital costs and post-operative
follow-up. Only one insurer covers donor operation and hospital costs alone and none
pay donor travel expenses. Should an existing customer require a transplant 1/6
companies would pay recipient medical expenses; this company would also pay donor
costs if the recipient and donor were both policyholders.
When questioned regarding sickness insurance, only 2/6 responders provide this product
and neither of these cover donation in their policy, both would provide sickness
insurance to a previous kidney donor.
All companies accept new customers after previous kidney donation although 2/6
stipulate that they exclude any problems arising from donation. When questioned
regarding the premiums for previous kidney donors, 2/6 charge an increased rate and 4/6
do not.
When questioned if the time since donation was a factor taken into consideration when
assessing new customers, 5/6 stated that it was. Time considerations are no longer
thought to be relevant after 3 months by 1/6, 6 months by 1/6, 1 year by 1/6 and 2/6 feel
that time considerations never cease to be relevant. One company admitted that the




Insurance companies providing life insurance to almost 80% of the life insurance policy
holders in the UK would honour the terms of their agreement should An existing
customer die as a consequence of live kidney donation. Results show that premiums are
not raised; therefore kidney donation has no long-term financial implications regarding
life insurance.
When considering new customers applying for insurance, there were significant
inconsistencies among both life and health insurers in the amount of time post-donation
that respondents considered relevant. Deaths associated with live kidney donation are
rare but occur predominantly in the peri-operative period as do the great majority of
complications and so these time considerations could be considered to be without
scientific foundation. Similarly the demonstration of a "full recovery", stipulated by
certain insurers is an inexact pre-requisite and clear definition such as stable normal
renal function or a return to work would be more helpful.
Kidney donation provides no medical benefit to the donor; however, the psychological,
familial, emotional and social advantages are well documented140 and described in
earlier chapters of this work. It has been postulated that the increased life expectancy in
donor populations' 141 may be attributed to exclusion of concomitant illness by the
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rigorous assessment process and to increased self-esteem after donation . Considering
this, the reluctance of certain health insurers to provide medical expenses for donors or
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sickness benefit is disappointing. Given the documented improved survival of live
kidney donor populations it is surprising that health insurance premiums charged by two
companies are higher than for age matched non-kidney donors.
In Sweden, donors are compensated for loss of income by social security insurance, the
recipients' county councils and the donors' employer140. This resulted in 80% of donors
receiving appropriate compensation in the 1990s. Whether a similar policy would
improve live donor rates in the UK is uncertain and would be an interesting subject for a
study.
Although kidney donation has no adverse financial sequelae regarding life insurance, it
could be argued that life insurance premiums should actually be reduced post-donation.
As not all UK insurers are included in this study, it would be prudent that prospective
donors should contact their insurance provider to ascertain their position prior to kidney
donation. Kidney donation has financial implications for health insurance. At the
present time, the long-term effects of this are minimised due to the structure of the
health service in the UK, however, future changes in health care provision may require a
re-examination of the stance of health insurance providers on this issue. The financial
security afforded by life and health insurance is of interest and importance to transplant
clinicians, nephrologists and insurance companies but most of all to patients. The
inconsistencies in many aspects of insurance provision to live kidney donors highlight
the necessity to share information and strive for evidence-based practice from insurance
providers.
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CHAPTER 6: LONGER TERM FOLLOW-UP
6.1: Introduction
During the assessment of potential live kidney donors, the transplant team invest much
time and effort ensuring each potential donor is medically assessed and fully informed of
risks. It is the belief of many that this duty of care should persist following donation. A
recent study examining donor's perception of their health after kidney donation included
statements of concern about the lack of contact with the transplant unit and nurse co¬
ordinator following surgery105. There are now increasing number of studies worldwide
reporting modes of long term follow up implementation and retrospective review of the
well being of living donors.
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One of the initial and well cited studies was by Najarian et al in 1992 in the USA " .
Fifty seven donors who had donated >20years previously were compared to 65 siblings.
In this study 32% of donors were taking anti-hypertensive drugs compared to 44% of the
siblings and 23% donors had proteinuria compared to 22% of siblings. The study found
no evidence of progressive renal deterioration in donors. In 1995 Kasiske et al analysed
48 studies with 3124 individuals who had undergone nephrectomy for donation, disease
or trauma and 1703 controls142. Nephrectomy caused a decrease in glomerular filtration
rate of 17 mls/min that improved with each 10 years of follow up by 1.4 mls/min. A
small increase in systolic blood pressure (2.4 mmHg) continued to rise by 1.1 mmHg
each decade and diastolic blood pressure was higher initially (3.1 mmHg) but did not
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continue to rise. A small progressive increase in proteinuria was also reported
(76/mg/day/decade). A study in Pakistan evaluated the outcome of 736 donors in a
dedicated live kidney donor follow up clinic and found that creatinine clearance fell to
87% of pre donation values at a mean time of 3 years (range 6 months to 18 years).
Hypertension developed in 10% donors and 24% had proteinuira exceeding 150mg/24
hours143. Grossman et al in Germany reported a review of 152 donors and found that
56% developed proteinuira (>150mg/day) although only 10% had albuminuria144. In
Sweden a study following 346 donors, hypertension was similar to an age-adjusted
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population, although approximately 10% of donors displayed proteinuria . No
accelerated loss of renal function was found after donation, however 3 donors developed
renal disease and 5 donors had a GFR below 30ml/min. This study recommended sparse
but continued follow-up of living kidney donors.
There are specific problems which live kidney donors may encounter particularly in the
early post-operative period which might not be obvious to health care professionals not
involved in dealing with such patients on a regular basis. Several issues remain
including how long should donors be followed up for and what form this follow up
should take. National registries, both in the UK and in other European countries are
being developed to obtain further information on the long-term outcome of donor
nephrectomy145.
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6.1.1 Establishment of living donor follow up clinic
The concept of establishing a follow-up clinic for live kidney donors in 1999 was two¬
fold: firstly, to ensure that patients make a satisfactory recovery following donation and
secondly, to obtain adequate information, collected prospectively, of the long-term risks
of kidney donation for future potential donors.
The objectives of the clinic were:
• To provide continuity of care by the transplant team following donation
• To monitor renal function and blood pressure, and ongoing medical status
• To provide a setting where the long term welfare of a cohort of live kidney
donors could be studied
The clinic was designed to be led by a transplant co-ordinator (qualified nurse) who had
specific responsibility for live kidney donation, and was actively involved in the
assessment of all live kidney donors. Permission to implement the clinic was granted by
the hospital authorities who agreed to fund the clinic on a trial basis. In consultation
with transplant surgeons and physicians, protocols were developed following standard
guidelines for assessment and care in line with other existing protocols within the
hospital.
There was concern that patients who had donated a kidney some years before might be
concerned by receiving a letter inviting them to attend a clinic after several years
without follow up. The purpose of the invitation and the establishment of recent
guidelines were quoted as reasons for establishing the clinic. In the event the majority of
patients were not concerned about being invited to re-attend the hospital. Where no
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response was received and the recipient was known to the unit the enquiries were made
with the recipient about whether further approaches should be made to initiate follow up
with the donor.
6.1.2: Clinic organisation
Donors were requested to commence a urine collection 24 hours prior to attendance.
They were asked specifically about problems with wound pain, and general problems
that may be attributable to surgery, and were also given the opportunity to ask any
questions which they may have regarding their donation or general health.
Following the appointment, any abnormal clinical results were discussed with an
experienced physician. The results were reported to the donor's family practitioner and
the donor by letter and on occasion the donor may be asked to re-attend the clinic for
further assessment.
Any problems related to abnormal blood tests adverse events or deterioration of renal
function were referred to a consultant physician for review and further management. In
addition the nurse had access for referral to the transplant surgeons and physicians who
were involved with the donor peri-operatively. In this way the clinic could be safely
manned by an experienced nurse who had security in the knowledge that there was a
clear line of referral for senior medical advice should this be necessary.
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The necessity of a 24 hour urine collection required to be clarified, as it was
inconvenient and a burden on the healthy donor. A further study was designed to
ascertain the most accurate, minimally invasive and least labour intensive method of
assessing renal function on an annual basis for living kidney donors.
6.2 Methods and materials
6.2.1 Follow up practice throughout the UK
To assess the provision of donor follow-up care in the United Kingdom the Transplant
Units were contacted at two time periods (1999 and 2003). The follow-up questions
formed part of the questionnaires requesting assessment information previously reported
in Chapter 1 of this thesis (Appendix 1 and Appendix 2). In both questionnaires the
respondents were asked about personnel involved, length and regularity of follow up and
investigations performed. Questionnaire 1 was sent to 31 centres in the UK in 1999 and
Questionnaire 2 sent to 25 centres in 2003.
6.2.2: Nurse-ledfollow up clinic
Since the first living donor transplant in 1961, 150 live donor kidney transplants had
been undertaken in the Transplant Unit in Edinburgh when the clinic was started in
1999. Where possible donors were traced and contacted initially by letter inviting them
to attend the clinic. All family practitioners were informed of the clinic and forthcoming
appointment. An audit was conducted to establish whether donors were satisfied with
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arrangements for follow up and the structure of the clinic. Donors were asked questions
concerning the convenience of clinic visits, personnel, flexibility and adequacy of
follow-up.
6.2.3: Estimation ofrenalfunction
A study examining the strength of relationships between estimates of creatinine
clearance and the Glomerular Filtration Rate (GFR) was instigated to establish the
predictive power of standard formulae for estimating creatinine clearance from serum
creatinine, and to provide evidence on the need for 24 hour urine collection. UK
Transplant and the Kidney Pancreas Advisory Group kindly allowed access to the
national database and data was analysed by Dr D Collett from UK Transplant.
Analysis was based on data from the National Transplant Database in the period from 1
November 2002 - July 2004 on living kidney donors in the UK. Data obtained from
donors prior to transplantation and data from donors recorded at the one year follow up
was used.
The strength of the relationship between creatinine clearance measured using 24 hour
urine collection (CC1) and the GFR obtained using radioisotope techniques was
explored. Since the GFR is not normally measured at the annual follow-up, pre-donation
data for living donors was used to examine this relationship in a group of healthy
individuals.
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Serum creatinine was measured in pmol/1, creatinine clearance and GFR were measured
in ml/min. All measures of creatinine clearance were corrected to give a value per 1.73
m2 of body surface area. Body surface area was calculated using the Gehan formula146,
according to which the body surface area (BSA) is given by: BSA = weight "SNS6 x height
042246
x 0.0235; where the weight and height of the donor are measured in kg and cm,
respectively.
From the measured serum creatinine level (SCr) the creatinine clearance was estimated
using three different formulae: The Cockcroft-Gault formula147; to Jelliffe148 ; Jelliffe
and Jelliffe123 (Appendix C). Other formulae, such as the MDRD149 equations and the
expression due to Nankivell et al150 were not used as these involve the values of
variables that are not recorded on the National Transplant Database. In the pre-donation
data set, the values of serum creatinine and creatinine clearance from urine collection
were those measured on the date closest to that when the GFR was measured, and not
more than 100 days pre-donation. In the post-donation data set, one year follow-up
records for donors who were assessed between 10 and 16 months after donation were
used. Data was recorded for 185 donors pre-donation and 99 donors post-donation,
however there were only 34 donors in common in the two data sets. Table 16 shows the
demographics of donors in each data set.
110
Table 16: Demographic characteristics of living kidney donors in each data set
Pre-donation Post-donation
Number of patients 185 99
Males 87 (47%) 42 (42%)
Females 98 (53%) 57 (58%)
Mean age (range) 46.4(18-71) 49.7 (24-72)
Mean height (range) 169.3 (146-198) 168.4 (152-188)
Mean weight (range) 75.0(43-112) 78.2 (47-116)
Demographics ofdonors pre andpost donation for estimation ofcreatinine clearance
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6.3: Results
6.3.1: Follow up practice throughout the UK
Twenty-nine responded to the follow up questions in 1999. When asked who arranged
follow-up of live kidney donors the transplant unit took responsibility in 28 centres and
in 11 this care was also coordinated jointly with the donors' general practitioners. One
centre relied solely on the general practitioner for follow-up of the donor. The duration
of follow-up of donors was reported as lifetime by 18 centres, 10 years by one centre, 5
years by two and 1 year by four. Following initial postoperative assessment no further
follow-up was arranged by three centres, and there was one non-respondent. One year
after organ donation, donors were seen every 6 months in one centre, annually by 19
centres and biannually by one. In the event of an unsuccessful transplant, counselling
facilities were provided for the donor by 15 centres but were not available in 12 centres;
no information was provided by two centres.
All 25 centres responded to questionnaire 2 in 2002. All 25 centres offered donor
follow-up, one centre for less than one year, one centre for five years and 22 centres
offered life-long follow-up. One centre did not respond. Personnel involved in follow-
up are displayed in Figure 15. All follow-up centres measured blood pressure and blood
chemistry, other investigations are displayed in Figure 16.
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□ Surgeon & GP
□ Tx Co-ord & Surgeon
□ Surgeon & Physician
□ Surgeon, Tx Co-ord & GP
□ Physician, Tx Co-ord & GP
■ Surgeon, Physician &Tx Co-ord
Personnel responsible for donorfollow-up in UK transplant centres in 2002(25 centres)
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Additional donorfollow up investigations in UK transplant centres in 2002 - all centres
measured bloodpressure and blood chemistry (25 centres)
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6.3.2: Nurse-ledfollow up clinic
Contact information was obtained for 47 living donors who donated between the years
1986 and 2000. Fifty-nine appointments were booked (47 new; 12 return) and 12 (20%)
donors did not attend. All the non-attendees were donors from the previous live donor
programme, who were not aware of the follow-up programme.
For the 35 new donors who attended clinic, creatinine clearance, serum creatinine and
urea were within acceptable limits for all donors. Three donors had raised random blood
glucose levels, 8.1 mmol/1, 8.6 mmol/1 and 9.5 mmol/1 respectively (normal range 3.6-
5.8mmol/l) and were referred to general practitioners for further management. Four
donors had trace protein on dipstick urinalysis; however, on laboratory measurements
protein was undetectable. One donor was attending a surgical clinic was ongoing wound
problems and 2 additional donors were referred to the surgeons for review. Eight donors
were found to be hypertensive at the clinic visit (170/90 -160/105 mmHg) and all were
referred to general practitioners. Two donors were taking antihypertensive agents.
The audit questionnaire was completed by 47 donors (35 new; 12 return) requesting their
views on the follow-up provided. Forty-three (91%) stated it was convenient to visit the
hospital; forty-six (98%) felt there was enough flexibility with the appointment and 47
(100%) agreed it would provide adequate follow-up. Thirty-eight (81%) were satisfied
with the follow-up they had received after kidney donation. When asked their
preference with regard to who should undertake their follow up, thirty-three (70%)
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stated a transplant coordinator with medical review, 3 (6%) would prefer general
practitioner and 1 1 (23%) stated that they had no preference (Figure 17).
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Donor preference forpersonnel involved infollow-up (47 respondents)
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Forty-two donors (89%) felt an annual review was sufficient, with the remaining 5
(11%) stating that it was not frequent enough. In situations where the donor found
difficulty in attending due to the geographic distance from our clinic, their local
transplant unit or general practitioner was contacted and arrangements were made for
donor follow up using our model. In these circumstances the results of investigations
were sent to the transplant unit for review.
6.3.3: Measurement ofserum creatinine, creatinine and GFR
The mean values of serum creatinine and measures of creatinine clearance for living
kidney donors in each data set (185 pre donation and 99 post donation), classified by age
and sex are displayed in Table 17. The post-donation serum creatinine levels were
substantially higher than those pre-donation, and the measure of creatinine clearance
was correspondingly lower. There were highly significant differences between the mean
values of SCr and CC1 between the sexes in the pre-donation group (p<0.01). Post
donation, the mean values of SCr and CC1 differ significantly between the donor age
groups, and the mean SCr values also differ between the sexes.
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Table 17: Values of donor serum creatinine and measures of creatinine clearance
Age group Sex Pre-donation Post-donation
SCr CC1 GFR SCr CC1
18-34 Male 95.8 111.3 115.7 115.5 85.4
Female 74.6 103.3 102.2 92.8 85.5
35-54 Male 99.9 109.6 110.7 124.0 81.6
Female 78.3 97.0 106.4 101.1 73.6
55-72 Male 97.8 98.0 93.2 137.6 69.6
Female 80.9 91.3 90.7 109.0 68.2
Mean values ofserum creatinine and measures ofcreatinine clearance for living kidney
donors in each data set, classified by age and sex: 185 donors pre donation and 99 post
donation
119
6.3.4: Pre donation data
For this group of patients, the values of GFR, CC1 and SCr are available for all but one
of the patients in the database. Linear regression analysis shows that there was no
evidence that the relationship between CC1 and GFR was significantly different between
the three age groups. However, there was evidence that the linear relationship was
different for each gender (p = 0.01), in that the CC1 was substantially higher for males
than females. There was a significant linear relationship between CC1 and GFR for each
gender (p = 0.008), although only 8% of the variation in the values of CC1 were
explained by the differences in GFR values between the patients, after allowing for
gender. Moreover, the slope of the straight line relationship is 0.22, which differed
significantly from unity. This indicated that the GFR was substantially underestimated
by CC1, for patients with higher GFR values, and overestimated at lower values. There
was also evidence that the distribution of CC1 values for patients with a particular GFR
was not symmetric, as there was a tendency for the larger values of CC1 to be more
variable. These features are apparent in a plot of CC1 against GFR, which is shown in
Figure 18. The fitted regression line is included in Figure 18.
Traditionally, the Cockcroft-Gault formula is used to provide an estimate of creatinine
clearance from the serum creatinine level, labelled CCIcg. For this group of patients,
there was a significant relationship between CCIcg and GFR (p<0.001), but the slope of
0.25 was significantly less than unity. Figure 19 shows a plot of the values of CCIcg
against the GFR, and the fitted regression line.
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Pre donation plot ofcreatinine clearance against GFR for male andfemale patients, the
GFR was substantially underestimated by CCl, for patients with higher GFR values, and
overestimated at lower values
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Figure 19: Revised Cockcroft-Gault estimate and GFR values pre-donation
2S0-
GrR
Cockcroft-gault estimates against GFR in pre-donation figures. There was a significant
relationship between CClccand GFR (p<0.001)
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Figure 19 shows less variability about the fitted linear relationship than in Figure 18,
suggesting that CClCo is a better predictor of the GFR than CC1. Very similar plots were
found when using the two estimates of creatinine clearance due to Jelliffe. The
correlation between each of the two Jelliffe estimates of creatinine clearance and GFR is
less than that for the Cockcroft-Gault estimate, indicating that for this type of patient, the
Cockcroft-Gault expression has greater explanatory power.
The results described in this section strongly suggest that for potential live kidney
donors, measurement of creatinine clearance through 24 hour urine collection does not
provide additional information about GFR than can be obtained from the Cockcroft-
Gault serum creatinine measurement.
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6.3.5: Post donation
In the analysis of this group, there were only 10 of the 99 patients in the data set for
whom the value of the GFR is available at follow up. For these patients, there was no
significant relationship between values of CC1 and GFR (p = 0.91), but there was a
strong linear association between the values of CCIcg and GFR post-donation (p =
0.009).
It was concluded that, as in the case for patients pre-donation, knowledge of the CC1
value from urine collection does not provide any information about the GFR over and
above the (limited) information from the Cockcroft-Gault estimate of creatinine
clearance derived from serum creatinine. The data available encompass a very limited
range of GFR values, from 49 to 67. This was because the GFR is only likely to be
measured directly post-donation when there is some concern about the donor's renal
function. Consequently, inferences drawn from this analysis are not necessarily
applicable to individuals with higher GFR values.
6.4: Discussion
Previous live kidney donor follow-up studies have concluded that further information
concerning the long-term renal function of those living with a solitary kidney should be
obtained by large multi-centre studies or national registries142. The principal focus of
live donor care has been on the assessment and perioperative care of the donor. It is now
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time that a similar emphasis was placed on the long term outlook of these individuals.
Many centres in this country and others did not have a structure for the follow up of live
donors. Part of the reason for this is that there is little evidence upon which to base
recommendations for follow up. Following guidelines that live donors should undergo
follow up life long a clinic was initiated for this sole purpose. It may be that as data
accumulate on the long-term postoperative outcomes of living kidney donation that the
duration, frequency and nature of follow up can be revised. Until such evidence is
available it will be necessary to audit outcomes of these patients through donor follow
up clinics.
The high attendance rate in this study suggests that live kidney donors value the
provision of long-term follow up, with acknowledgment of on-going care from the
transplant team. The preliminary audit results confirm acceptability of a nurse-managed
service. In addition attendees commented that they appreciated the flexibility of the
appointment system. It is essential that donors who live outwith reasonable travelling
distance to the transplant unit receive similar care to those attending the central unit and
for this reason a follow-up proforma was established which is provided to family
practitioners or referring renal units to facilitate this aim. With many transplant centres
aiming to increase the number of live kidney donors, adequate resources should be made
for follow-up. It is anticipated that one benefit of live donor follow up clinics is that it
will enable improved quality of data that may be used to provide more accurate
information for future live donors.
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In 2000 the British Transplantation Society/Renal Association Living Donor Guidelines
recommended the lifelong follow-up of all kidney donors and the United Kingdom
Transplant database has prospectively collated data on living donors from 2002. Thus
follow-up of living donors is now routine in the UK, although investigations performed
vary across centres, as previously no clear guidelines have been issued with
recommendation of appropriate interventional investigations required for this group.
Donor attendance must be encouraged and lifestyle disruption should therefore be
limited. The objective of creatinine clearance study was to balance the safety and
accuracy of estimation of renal function with minimal inconvenience for this otherwise
healthy cohort of people.
Neither CC1 nor the estimate derived from the Cockcroft-Gault formula are particularly
strongly associated with GFR in healthy patients. However, the information about this
post-donation is somewhat limited, as the GFR is only measured in about 10% of
patients at the one year follow-up. The main message from the analysis was that
estimates of creatinine clearance derived from 24 hour urine collection, or estimates
derived from the Cockcroft-Gault formula do not correlate well with GFR in living
kidney donors.
If the GFR is not to be used to provide a value for creatinine clearance, the Cockcroft-
Gault estimate derived from the serum creatinine level leads to a more precise estimate
of creatinine clearance than the CC1 value. There is little to be gained from requiring
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patients to obtain 24 hour urine sample as part of the annual follow up process.
However, it is recommended that a spot urine sample should be tested for proteinuria.
The model for live donation presented here may not suit all centres, particularly those
where the geographic distance of the donors precludes their attendance at a central unit.
It is hoped that the principles that have been established will provide a useful model for
other centers wishing to establish similar clinics.
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CHAPTER 7: CONCLUSION
7.1: Renal failure and transplantation
Developments in transplantation over the past half century have both addressed the
problem of end stage organ failure for many patients and their families and also
presented us with new challenges and ethical dilemmas. The replacement of an organ is
a concept that was a vision in medieval times and is now accepted as a routine treatment.
In a similar way we can anticipate the developments in the future with stem cell therapy
and xenotransplantation as perhaps solving the problems of organ shortage but
presenting us with a new set of complex ethical and moral issues.
The history of transplantation is a fascinating and well documented field. The pioneers
of transplantation such as Sir Peter Medawar and Joseph Murray became Nobel prize
winners for their work7'9. Without the experimentation and ingenuity of these individuals
in the 20th century, organ and tissue transplantation would not have reached the standard
achieved today. Perhaps one of the most intriguing aspects of transplantation is the
combination of technical, clinical and scientific knowledge required to allow progress
and success. Sir Roy Calne commented that the whole attitude of the medical profession
changed with the introduction of cyclosporine. Before that, he said, "transplantation was
regarded as an enterprise for mad surgeons ignorant of immunology who really didn't
know what they were doing and who obtained unpredictable results" 151. Fortunately
surgeons such as Sir Roy Calne were far from ignorant of immunology and his
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combined technical skill and research into immunosuppressive therapy resulted in
transplantation moving from experimental stages to the preferred treatment option we
know today.
Much work has also been done to develop 'bridges' to transplantation. Today many
patients will view dialysis as a temporary life saving measure necessary until an organ
becomes available. However the development of haemodialysis in the mid 1900s has
proved to be as life saving as transplantation and is now available to a much larger group
of patients. Unfortunately for those with end stage liver, cardiac and respiratory failure
the therapeutic options are not so sustainable - thus deaths on these transplant waiting
lists are higher in percentage. Improvements in treatment and a range of innovative
support devices have still not removed the need for transplantation.
The cost of renal failure is not purely financial. The medical and social implications of
end stage renal disease affect individuals from all spheres of life. Most kidney diseases
are not self inflicted through abuse of drugs such as alcohol, smoking or other
substances, and thus cannot be circumvented by public health education. Careful
adherence to diet and medication can prolong native kidney function to a certain extent,
although for many the requirement for renal replacement therapy is an inevitable reality.
Our aim is to provide the best possible treatment for patients in these circumstances and
combine clinical and social knowledge to ensure the benefits of a particular treatment
outweighs the risks. In the reality of day to day clinical medicine this can be extremely
difficult and for those working within transplantation each individual patient can appear
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to challenge the knowledge and decision making ability of even the most experienced
clinicians.
Research and evidence-based practice provide a strong framework to base decisions
upon. We know far more now about the mechanics of organ rejection than even 20 years
ago, yet there can still be the rare situation of an acute rejection in which the graft cannot
be saved. The immunosuppressant agents available today for the most part can prevent
such rejection, but must be balanced with the safety of the patient so they are not so
immunocompromised that an overwhelming infection causes serious consequences. The
shortage of organs has demanded that more marginal donors now proceed to donation
and the recipient may be at more risk of receiving a poorly functioning graft that may
expose them to foreign antigens. The opportunity of subsequent transplantation may be
reduced due to this sensitization.
Clearly the best option for many of these patients with end stage renal failure is a
transplant from a living donor, both from a clinical and social viewpoint. The focus of
our study has been to ascertain that we can safely promote living donor transplantation
within the United Kingdom. There will always be individual circumstances that present
where we cannot anticipate the correct answer - but by building on this knowledge and
experience we are in a stronger position to advise and set standards of acceptable
practice.
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7.2: Increasing Organ Donation in the UK
Countries such as Norway and the USA compensate for lower deceased donor rates with
enthusiastic living donor programmes, whereas in Spain, with the highest organ donor
rate in the world, living donor transplants feature to a lesser extent (Table 18). In certain
parts of Asia where the concept of brain stem death is not accepted the transplant
candidates rely solely on living donors, although this is slowly changing. This
worldwide overview does suggest that live donation 'fills the gap', and reflects the fact
that although clinically live donor transplants may be a good option for patients, the use
of organs from deceased donors is preferable.
The ratio of living donor and deceased donor transplants in countries such as Norway
and the USA should not be unrealistic targets for the UK. There are geographical and
organisational similarities between Norway and Scotland, and although Scotland does
maintain a reasonable living donor rate there are key operational differences that clearly
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Table 18: Organ donation rates per million population worldwide 200444
Country Living pmp Deceased pmp Non-Heartbeating pmp
France 3.5 21 0
Norway 20.7 19.6 0
Pakistan 15.1 0 (4 donors) 0
Spain 1.8 34.6 1.8
UK 8 12.3 1.5
USA 23.8 24.4 0
Comparison oforgan donation rates per million populationfor living, heartbearting and
non-heartbeating donors
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do impact upon the number of transplants performed. In Norway the policy of not
adding a patient's name to the transplant waiting list until live donation has been
explored with all potential donors differs considerably from the UK. Donors are
contacted directly by the nephrologists in Norway, whilst the UK operate a strict policy
that the potential donor must initiate contact and drive the donation process. Would the
UK be ready to adopt a more direct approach to family members?
The increase of living donor numbers in the USA is probably partly driven by economic
considerations. Medicare will only pay 80% of dialysis costs - thus the financial impact
on a family can be considerable152. In the UK all dialysis expenses are met by the NHS,
indeed patients can actually be in a poorer financial position with a functioning
transplant. This is due to the social security benefits system recognizing renal failure as
long term sickness and benefits awarded accordingly. When a patient receives a
transplant these benefits may be withdrawn. Similarly, prescription charges are waived
for patients on dialysis however this waiver does not apply to immunosuppressants post
transplant.
So if we examine the worldwide organ donation rates a clear picture emerges - those
with higher deceased donor rates do not rely on living donation and vice versa. Within
the UK we are attempting to increase both sources. Unfortunately the deceased organ
donation rates are limited by a more fundamental lack of resources compared to other
countries - the provision of intensive care beds in the UK is 0.8% of acute hospital beds
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compared with 3-5% in other European countries and 10-12% in the USA153. The
number of families refusing to donate organs does vary in accordance with media
reporting, but rarely drops below 30% in any region46. Changes in the law in both
England and Scotland will place greater emphasis on the wishes of the individual during
their lifetime, though the support of families will still be required in practice if not in
law.
7.3: Increasing living donation in the UK
Following the Quinquennial Review of the United Kingdom Transplant Support
Services Authority (UKTSSA) 1998-1999, the newly formed UK Transplant was
awarded funding to maximize the number of solid organs donors within the UK. The
2001 UKT Business Plan aimed to increase the number of living donor transplants to 15-
20% of the renal transplant waiting list. This was implemented by funding Living Renal
Donor Co-ordinator Schemes throughout renal units in the UK. In November 2004 this
initiative was reviewed, alongside others such as the non-heartbeating donor scheme and
donor liaison scheme134.
The living donor scheme was found to be extremely cost-effective, as the average
increase of 63 donor kidneys per year would be expected to lead to 189 transplants over
the three year period. This would translate into a cost benefit of £36 million over a nine
year period (taking the nine-year median graft survival time of a transplant patient not
requiring dialysis). The outcome of the review of the scheme was to recommend that UK
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Transplant continued to fund living donor transplant co-ordinators in the long term154.
Figure 20 displays the increase in living donor transplantation in the UK over the past 10
years.
















Steady increase in number ofliving donor kidney transplants in the UK 1995-200546
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The recommendations that UK Transplant continue to fund transplant co-ordinators in
the renal units in the UK is positive and encouraging for this group of specialist nurses.
Within the NHS there is a growing acceptance of the requirement for nurse practitioners
to lead and assume responsibility for specialized programmes, supported by the
Department of Health report 'Making a Difference' in 1999 recommending that
experienced nurses be retained and rewarded to help improve quality of services155
The study concerning the assessment of potential living donors showed that in 1999 only
20 of the 29 transplant centres responding employed a designated transplant co¬
ordinator/nurse practitioner to manage live donor transplantation, by 2002 all 25 centres
performing live donor transplants had a living donor co-ordinator. The British
Transplant Society Guidelines recommend that a designated live donor co-ordinator is
considered optimal and that transplant co-ordinators play a key role in organizing the
assessment and surgery for donor and/or recipient. Such individuals generally become
closely acquainted with the patients and their families and may be best placed to provide
the necessary support, even in the context of adverse events prior to or following
transplantation53.
Streamlining and having a key person to organize the assessment process may partly
explain the increase in living donor transplantation over the past 5 years. In addition the
provision of National information booklets and other local educational material
alongside targeted patient information sessions and high profile media coverage has
clearly had a positive impact on numbers. The recruitment of potential living kidney
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donors depends on all members of the multi-disciplinary team working in close co¬
operation and ensuring equity of access to the potential of living donation. The methods
of recruitment of living donors varies widely and is the subject of ethical debate. In
some centres all potential recipients and their families are asked automatically whether
they would consider living donation. In others a more passive approach is made with the
provision of information about living donation but leaving the responsibility to the
recipient and their family or friends to broach the subject. There is no real evidence over
which is the best approach. A direct approach may recruit more potential donors but may
make some individuals feel pressurized which is undesirable. A passive approach may
miss donors but is likely to ensure that those that do come forward are well motivated.
The best approach is probably somewhere in the middle ground with a more detailed
explanation of the potential for living kidney donation but avoiding direct questioning.
Such an approach requires that all members of the team are conversant in the issues
surrounding living donation. Furthermore, no living donor programme can function
without a surgeon willing to take responsibility for removing a kidney from a healthy
person.
7.4: Selection of living donors
Our study of donor selection throughout the UK at two time points displayed that despite
the introduction of national guidelines for the assessment and selection of living donors
there still remains a disparity in both the physical and ethical selection process. This
perhaps reflects the very real concern amongst some clinicians about living kidney
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donation and their interpretation of minimum risk to the donor with maximum benefit to
the recipient.
There is very little research concerning the donors who are 'turned down' for medical
reasons - especially those borderline cases where, understandably, the safest course of
action for the potential donor is not to undergo an operation. The donors who are
advised not to donate for these physical reasons may feel angry or resentful that they
have been denied the opportunity to improve the health and life of a close family
member or friend. Anecdotally, again depending on the relationship, there can be a
feeling of relief when the donor is told they should not proceed - one could argue these
people should perhaps not be donating at all if they feel relieved that they have been
sound unsuitable, conversely it is surely a normal and appropriate human response to
feel relieved by avoiding a major operation and associated implications. There is future
scope for further study in this area, examining both the physical and emotional response
to non-donation.
Perhaps the most interesting question that the assessment questionnaires raised was the
balance of the rights of the donor (and recipient) and rights of the clinical team involved,
especially the surgeon. Kidney donors are by definition otherwise healthy individuals
and derive no health benefit from renal donation. There is an argument that donor
selection should be made entirely separate from recipient influences, however the
potential donor may contest this statement. For example, a woman in her 50s who has
borderline renal function may be much more insistent on donating to her child or partner
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rather than an age matched sibling. The incentive to donate, whether it be emotional or
practical, can never be underestimated.
The General Medical Council has issued guidelines on the ethical considerations of
gaining patients' consent. The potential living donor does fall into a different category to
the majority of consent issues - not performing the procedure would physically be the
best option for the live donor. The GMC states in the 1998 guidelines on Seeking
Patients' Consent: the Ethical Considerations that 'it is for the patient, not the doctor, to
determine what is in the patient's own best interests. Nonetheless, you may wish to
recommend a treatment or a course of action to patients, but you must not put pressure
on patients to accept your advice'156. So where does this leave the surgeon who does not
think it is in the potential donors' best interest to proceed to nephrectomy? Under the
auspices of conscientious objection, the doctor can refuse to treat and refer to another
clinician.
However, there has been a gradual shift away from a philosophy of paternalism to one
that recognises the patient's right to make his or her own decisions about the care he or
she receives. Respect for an individual's autonomy is the central reason that each person
has the right to consent to or refuse treatment. Individuals can exercise their autonomy to
make decisions about their care only if they have the necessary information about the
choices available and the potential consequences of each course of action51.
Living donor transplantation continually presents complex medical dilemmas to which
even the most experienced clinicians in transplantation cannot readily provide an
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answer. This is partly due to the thorough investigations that the potential donor
undergoes prior to donating. When a patient has a diseased organ or tissue that requires
to be removed or repaired, there is a clear potential benefit for the operation to proceed
and the patient undergoes a basic screening to ensure they are fit to survive an
anaesthetic and operation. These issues become far more complex in the assessment of a
live donor. The three areas of clinical assessment - immunological compatibility; renal
function and general health can all require detailed investigation and raise decision
making issues. The social and psychological issues have equal importance to physical
assessment. One of the most ethically controversial areas within living donor transplant
is providing the donor with a medical alibi - e.g. providing a reason for the donor not to
proceed if they wish to withdraw at any time. This practice is universally accepted
within the transplant community and rarely would a potential donor object to be offered
this 'opt-out' clause. However, extreme care and caution has to be employed in this very
sensitive area. No health professional should be put in the position of providing incorrect
information to a family, even in the best interests of the donor. Likewise, the potential
donor should not feel any added guilt at withdrawing by having to lie to the recipient.
Since 2001 UK Transplant having been collecting detailed information on all living
kidney donors in the UK. This data set includes assessment information such as blood
pressure, serum creatinine, haemoglobin, isotope glomerular filtration rate, estimated
creatinine clearance, urinalysis, weight and height. Details of any co-morbid conditions
have been requested and any further cardiac investigation required at time of assessment.
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This information will provide a valuable database for assessment criteria, linked with the
similar follow up data provided.
7.5: Quality of Life
Throughout the many and varied definitions of quality of life cited in the literature, there
does appear to be a basic agreement that the measurement of quality of life depends
upon an individual's subjective concept of their current situation in life. This is an
important factor in the measurement of health-related issues, as two people with the
same health status may have very different perceived qualities of life94.
One of the key points in assessment of quality of life is the individual's perception. The
'disability paradox' has been demonstrated in some studies that have shown that patients
with serious and persistent disabilities score their quality of life higher than many
external observers would anticipate157. This theory may be tested in the unique field of
transplantation when a person with a chronic illness receives an intervention that
improves physical disability and allows freedom from dialysis.
Within all forms of quality of life assessment there will always be debate and argument
concerning the correct tool to utilize. The World Health Organisation Quality of Life
questionnaire (WHOQOL) was selected for our study as it had been validated cross-
culturally (and was to be utilized in two centres) and was designed to assess both well
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and ill people. A renal disease specific questionnaire would have probably provided
more detailed information concerning the recipients, but would not have provided any
comparative measures to analyse. This was particularly and encouragingly substantiated
in our findings that the donor physical domain quality of life was significantly higher
than both the UK and world well average score pre donation.
We chose time points of pre-operation; six weeks post and one year post operation. The
pre-donation time was within two weeks of the date of operation, and all pairs had
completed the assessment and were in the final stages of preparation. This is obviously a
time of high anxiety for any person awaiting an operation, and especially for the donor
who does not physically require this surgery. It is therefore surprising that donor's
scored so highly in the psychological domain, and may reflect a strong feel-good factor
about the reason for donating.
The average recovery time after a major operation is expected to be 6-12 weeks, and all
donors attend the transplant centre or referral centre for a post-operative assessment at
around six weeks to assess recovery. Data collection for UK Transplant has indicated
that for recovery from donor nephrectomy (open technique) to average between 8 and 12
weeks to return to previous level of fitness; thus the six weeks mark would indicate for
the donor the latter stage of recovery. For the recipient, the level of kidney transplant
function at one year is a reliable indicator of long-term graft survival. We chose one
year as an end point for this study due to these two factors, although there would be
interest in continuing and monitoring both donor and recipient for longer term.
142
The questionnaire design for the relationship issues was performed in consultation with
Professor Power, University of Edinburgh, a member of the World Health Organisation
Quality of Life Assessment Group and a leading expert in this area. A balance was
sought to provide a range of options, both positive and negative for the donor and
recipient. The questions were straightforward and avoided ambiguity and the format
remained the same for all three questionnaires, although some of the questions
necessarily required to differ. Possibly the most important factor in the completion of
these questionnaires was to ensure that donor and recipient completed them separately
from each other, as there would have been strong confounding factors if they had
completed the questionnaires in each others presence.
The study was initially designed as a single centre study but was easily adopted by a
further transplant centre. The reason for extending the study to Addenbrookes Hospital
in Cambridge was to increase the numbers within in the study, rather than comparing
any cultural or social differences. Both centres have similar practices and are size
matched in regard to living donor transplantation. In retrospect, due to the nature of
transplantation within the UK, with only 25 centres now performing living donor kidney
transplantation, it may have been feasible for other centres to adopt the study and
provide greater numbers.
From the fifty-two pairs who agreed to participate in the study there were 12 donors and
17 recipients who did not complete the questionnaire at all three time points (one
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recipient died). The majority of the non-completers lived geographically further away
and did not attend the transplant centres for follow-up and relied on postal completion.
There was clearly an advantage of knowing the participants and ensuring the
questionnaires were completed during a routine clinic visits. Average questionnaire
response rates are 15% when relying on postal return and this was confirmed with our
study. The fact that relationships had been built and the donors and recipients were in
the hospital clinic may suggest an underlying coercion to complete the questionnaires.
Conversely, due to the nature of living donor transplantation most people are very keen
to assist and help inform future donors. This was certainly the common response within
our clinic settings.
The value of our findings examining the quality of life and relationship issues are two
fold. The assessment process is inevitably an extremely stressful time for donors,
recipients and families. Within the clinic setting it is often described as a 'rollercoaster'
of emotions ranging from anxiety, impatience, apprehension, sometimes anger and
frustration. Contrary to usual hospital practice we ask the donors to move the assessment
forward, ensuring that they are not being coerced by hospital staff to undergo
investigations. The recipient has to take a sideline during the donor assessment, which
sometimes must be hard to accept as the process is intended for their benefit. Other
family members may feel excluded as the selected donor and recipient are the primary
focus. During this assessment time the transplant team gains a privileged insight into
family dynamics, coping mechanisms and motivation. This information may be
invaluable at the time of transplant, especially if complications occur.
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When all investigations are complete and the donor, recipient and family are willing to
proceed with the operation, having been made aware of all the risks, both general and
specific to that donor and recipient, a date is set for the transplant. At this time there is a
subconscious shift of emphasis. The early part of the assessment sometimes appears to
be spent informing the family of many negative aspects, with an acknowledgement of
the benefits to the recipient. In many live donor pairs, when they are informed of the
transplant date, the reality of the situation appears to impact. This is perhaps due to relief
that the investigations are deemed satisfactory, but also that actually the operation is
going to happen and there is a focus shift towards this. It is very important that the
health professionals move with this shift, and support the decision made.
To this end, the information provided necessarily will concentrate on the practicalities of
the admission arrangements, pre-dialysis, transport and family support. To date, there
has not been a great amount of evidence to base psychological support at this time, other
than reporting the retrospective studies such that donors do not regret donating, are not
adversely affected in the long-term and most recipients experience an improved quality
of life and health. This research has provided an in depth, evidence based study to report




• Careful donor selection ensures that individual's quality of life score is above the
UK and world average (physical, psychological, social and environmental) pre
donation.
• Six weeks after donation, physical quality of life is the same as a healthy person
in the UK, returning to above average at one year. Psychological, social and
environmental scores remain above the UK and World norm.
• The relationship with the recipient continues to improve over the year time
period, relationships with family members does not alter significantly.
• Most kidney donors do not appear concerned about living with one kidney.
• Most kidney donors would donate again, if this were possible.
Transplant recipients from living donors
• Physical quality of life of patients with renal failure is significantly lower than
that of the UK and World norm, psychological, social and environmental scores
are similar.
• Within six weeks of a successful transplant, physical quality of life improves
almost to the world average, within a year to the average well person in the UK.
• Relationships with both the donor and family members improves over the one
year time period.
• The recipients have a high level of concern about the donor before the transplant,
this is much reduced after the operation.
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The second value of the findings is to provide evidence to health professionals in all
areas of medicine. Ensuring equity of access to living kidney donation relies on
awareness of all potential referring sources, including general practice, nephrology units
and transplant centres. Reassurance that the selection of only the healthiest donors
results in successful donation and transplantation is a strong and positive message. In
addition, for those individuals who are found not to be suitable as donors due to physical
or psychological reasons, the follow-up care is often passed back to general practitioners
or referring units. Again this raises the question of how these individuals fare when not
allowed to proceed. A further point that may be argued is that we are too selective with
our donors, and that may deny people the right to enhance quality of life for the
recipient. Only by selecting more marginal donors will this be proven - but this
increases the risk of serious short and long term complications. Each individual case has
to be assessed using the maxim of minimum risk to the donor with maximum benefit to
the recipient33. The death of the journalist Mike Hurewitz in Mount Sinai Hospital New
York, following a living liver donation to his brother sent shock waves around the
world. The story was featured on the front of Time magazine and on every major
broadsheet newspaper. This adverse publicity was responsible for the suspension of the
programme and a down turn in the number of individuals coming forward as living liver
donors. We do not wish to be faced with a similar situation to this, as the UK wide
impact of a donor death would seriously affect many programmes and as least
temporarily reduce the number of live kidney donor transplants performed.
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7.6: Follow-up
For many live kidney donors, due to relative absence of past medical history, admission
to hospital for donor nephrectomy may be the first experience of surgery and the
associated risks. The usual scenario would have been as supporter for their relative with
renal failure. Preparation for this surgery therefore must include awareness of both the
major and minor complications that may occur. Our study demonstrated that major
complications in the two centres, Edinburgh and Cambridge during the retrospective
study, are very rare, but on two occasion donors required blood transfusion for
haemorrhage. Minor complications are more common than we had anticipated, and this
study provided data both to provide information for donors and clinicians and also to
review and change practice.
Possibly one of the most important observations has been the post-operative pyrexia in
the absence of infection. Administering antibiotics unnecessarily is best avoided, and we
have adopted a policy of not treating on the basis of pyrexia alone. Early physiotherapy
intervention and mobilization has been instigated to reduce atelectasis, and although
smoking was not correlated with a higher complication rate in our study due to low
numbers, we do encourage potential donors to stop smoking prior to surgery.
The incidence of epidural complications, although low, gave rise to concern and review
of policy was implemented. All donors are offered an epidural as standard post operative
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pain relief and the hospital pain relief teams are informed of forthcoming donor
nephrectomies. Epidurals are only performed by a member of a dedicated team of
consultant transplant anaesthetists and the donors are reviewed by the hospital pain relief
team on a twice daily basis. Constipation, although considered a minor complication,
was a common complaint post-nephrectomy and prophylactic measures were introduced.
Future work is required to measure the impact of these changes in protocol. In addition,
data collection by UK transplant concerning immediate peri and post operative
complications in all donor nephrectomies throughout the UK will provide a large series
of data, although this does depend on reporting criteria by centres and may just provide
information on major complications.
If there is reasonable satisfaction that the immediate affect of living donor transplant is
beneficial to both the donor and recipient in the short term, the longer term
consequences also require examination. Further study aimed to establish the balance of
follow-up required for this group of individuals. It is known that pre operation they are
in good health and are estimated to have sufficient renal function to cope with one
kidney in the long-term, what level of on-going monitoring is required?
As with assessment criteria, there was disparity throughout the UK with regards to donor
follow-up. This has been addressed by UK Transplant collecting annual data concerning
all living kidney donors, however it does depend on donors attending clinic or their
general practitioner. Since UK transplant commenced this data collection 32% of donors
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who donated in 2001 have been described as lost to follow-up. The reasons for this non-
attendance at follow-up clinics may be due to a number of donors having traveled from
abroad to donate a kidney here in the UK - with geographically spread families this is
not uncommon. The other likely reason is healthy persons do not like taking time away
from work to attend clinic when they do not feel unwell.
When the follow-up clinic was commenced we asked for donors to bring a 24 hour urine
collection to estimate creatinine clearance. It soon became clear that this was an
inconvenience and prompted a study concerning the estimation of renal function by
alternative methods. With the study outcomes suggesting that Cockcroft and Gault
estimation was more reflective of GFR than 24 hour urine collection for normal kidney
function practice was altered. One further concern was protein measurement and
agreement was made with the Clinical Chemistry department to perform urinary albumin
quantification on any donor who had trace or above proteinuria on dipstick during
routine follow-up.
As the follow-up clinic is a relatively new concept in terms of time, long term
attendance rates will dictate the success of the venture. There appears to be a general
acceptance of a nurse-led service. One aspect of the clinic being within the transplant
setting rather than deferred is provision of support if the recipient graft fails. There can
be a sense of loss or failure, despite the time interval and it is important that the donor
has an opportunity to express emotions and discuss with a member of the transplant
team.
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Whilst the follow-up data for living kidney donors is encouraging, inconsistencies
remain with insurance companies concerning the recovery period and associated short
and long term risks. Potential donors are still advised to check with their insurance
companies pre donation to ensure adequate cover in the short and long term. Donors
should not be financially compromised by the act of donating a kidney. Recent
guidelines from UK Health Departments have advocated reimbursing donors for loss of
earnings as allowed by the 1989 Human Tissue Act (this also will be stated in the new
Human Tissue Bills). In practice this is the responsibility of the health board of the
recipient and not uniform across the UK. More work is required to ensure that donors
receive equal treatment in this regard.
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7.7: Summary
The chronic shortage of organs for transplantation has demanded that we look to all
sources to increase organ availability. There is scope in the UK to increase the number
of living donor transplants compared to other countries and the aim of this research was
to examine current practice and improve standards of living kidney donor
transplantation, so that this procedure can be confidently advocated as a treatment
option. The study had five aims: 1) To establish the living donor assessment, selection
criteria and follow up practice throughout transplant units in the United Kingdom; 2) To
measure the impact on quality of life and relationship issues for both donor and
recipient; 3) To ascertain if the act of donating a kidney causes short or long term
physical or psychological harm; 4) To determine the optimum follow-up practice for
living donors; 5) To explore whether we can improve the standards of living donor
transplantation.
The study found that there remains variety in practice throughout the UK in procedures,
although publication of national guidelines has provided a valuable framework. Careful
donor and recipient selection results in successful outcome and should encourage living
donor transplantation to continue and increase throughout the UK.
It was demonstrated that with rigorous donor assessment only those above UK average
physical quality of life scores proceed to donation. The donors experience a transitory
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decrease in quality of life following the operation and have a small risk of major and a
higher risk of minor complications. Longer term the donors are not compromised by
physical or psychological difficulties and experience an improved relationship with the
recipient.
The clinical benefits of living donor transplant for the recipient are well-recognised and
the assessment process appears to preclude those who may suffer psychological
impairment from receiving a kidney from a living donor in our study group. The
recipient enjoys an improved quality of life and relationships with both the donor and
other family members. High level of concern about the donor decreases after the
operation.
Annual follow-up is provided for those donors who wish to attend and the majority of
donors do not worry about living with one kidney.
Practice has been adapted in response to findings and will be monitored to assess long-
term effect. The study findings can be utilised to provide information for potential
kidney donors, recipients and their families.
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LIVING DONOR ASSESSMENTAND FOLLOW UP
QUESTIONNALRE
PLEASE TICK APPROPRIATE BOX:
1. Does the assessment team use a written protocol? YES □
noD
2. During the assessment work-up, are the donor and recipient seen:
TOGETHER□ SEPARATELY □ BOTHD
3. Are all potential donors assessed by:
Transplant surgeon YESD NOD Renal physician YESDNOD
Transplant Co-ordinator YES □ NO □ Independent Medical Assessor YES □ NO □
Please circle person in overall charge ofthe assessment.
4. Are potential donors assessed by a psychologist?
Living related YESDNOD REFERRAL OPTION YESDNOD
Living unrelated YESDNOD REFERRAL OPTION YESDNOD
5. Is there an agreed time lapse between initial assessment and
operation date?
NONED 3/12D 6/12D OTHER
6. When is the name of the recipient removed from the cadaveric list?
WHEN DONOR ASSESSMENT COMPLETE □ DATE OF OPERATION □
OTHER
7. Please tick ROUTINE clinical investigation requests:
BLOOD TESTS:
Full blood count (FBC) D
Urea and electrolytes (U & Es) D




















Urine for microscopy D
24 Hour urine for protein & creatinine clearance. □
Isotope Glomerular Filtration Rate (GFR) D
Erect and Supine Blood Pressure(BP) D
Serial BP monitoring □




Please list other standard investigations:
8. EXCLUSION CRITERIA:
AGE: Please tick age of potential donors that would NEVER be considered:
<14yrsD <16yrsD <18yrsD <21yrsD <25yrsD
No minimum age □ Other
Please tick MAXIMUM age of potential donors:
55yrsD 60yrsD 65yrsD 70yrsD 75yrsD 80yrsD
No maximum ageD Other
Would you consider child to parent donation? NEVER □ EXCEPTIONALLY □ ALWAYS □
FEMALES WITH CHILDBEARING POTENTIAL:
ALWAYS EXCLUDED □ SOMETIMES ACCEPTED □ ALWAYS ACCEPTED □
OBESITY: Please tick accepted EXCLUSION weight:
□ <10% OVER IDEAL BODY WEIGHT
(eg. ideal body weight of 70kg - patient is <77kg)
□ <15% OVER IDEAL BODY WEIGHT □
(eg. ideal body weight of 70kg - patient is <80.5kg)
□ <20% OVER IDEAL BODY WEIGHT
(eg. ideal body weight of 70kg - patient is <84kg)
NO EXCLUSION CRITERIA □
OTHER
Please tick EXCLUSION result in the following scenario:
50 year old woman who weighs 60kg -
Creatinine Clearance: (mL/min/1.73m2)
<70□ <80D <90D <100D <110D OTHER.
Would you EXCLUDE a potential donor who has the following:
DIABETES: Fasting blood glucose >6.0 YESO NOD
Family history of diabetes YES □ NOD
Other exclusion criteria
HYPERTENSION: Does your unit define criteria for
hypertension as a contraindication to living donation? YES□ NOD
IfYES please define
WHO classification: mild hypertension:systolic 140-180 and/or diastolic 90-105(mmHg)
borderline hypertension: systolic 140-160 and/or diastolic 90-95
Ifwe accept the World Health Organisation (WHO) classification for mild and
borderline hypertension then please tick ifyour unit would EXCLUDE in thefollowing
scenario: A 40 year oldfit male -
Normotensive taking one anti-hypertensive agent with no evidence of end organ damage
(ie no left ventricular hypertrophy or microalbuminuria)
Hypertensive on no medication with no evidence of end organ
damage
Borderline hypertension with evidence of end organ damage





OTHER: Wouldyou EXCLUDE a potential donor who:
Has learning disabilities: MildYESdNOD Moderate YES□NO□
Is an alcohol abuser YES □ NO□ Is a smoker (>20/DAY) YES □ NO □
FOLLOW UP:
9. Are donors followed up by:
TRANSPLANT UNIT□ INDEPENDENT MEDICAL ASSESSOR^
GENERAL PRACTIONERD NO FOLLOW UP □ OTHER
10. One year after transplant, how often would the donor be reviewed?
6/12D 12/120 24/120 OTHER
11. For how long would the donor be followed up?
1YEAR0 5 YEARS 0 10 YEARS 0 LIFEO OTHER
12. Is formal counselling available for the donor if the transplant fails?
yesOnoO
13. How many renal transplants were performed in your unit in
1997 (1st Jan - 31st Dec)? CADAVERIC
LIVING RELATED
LIVING UNRELATED
14. What size ofpopulation does your unit serve?
15. Who completed this questionnaire?
TRANSPLANT CO-ORDINATORD TRANSPLANT SURGEON□ BOTHD
OTHER
Ifyou have a written protocol I would be most grateful ifyou would enclose a copy.





Royal Infirmary of Edinburgh
Lauriston Place
EDINBURGH
Live Kidney Donor Assessment
1. How many renal transplants were performed in your unit in 2001 (1st Jan-
31st Dec)?
Cadaveric Live related Live unrelated
2. Approximately how many potential donors are you currently
assessing?
3. During the donor assessment process, please tick who of the following is
routinely involved?:
Live related Live unrelated Referral option
An Independent Medical Assessor □ □ □
Psychologist □ □ □
Psychiatrist □ □ □
Social worker □ □ □
Which relationship pairings would your unit undertake? Please tick:
Done in past Perhaps in Neve
the future
Parent to child □ □ □
Sibling □ □ □
Child (>18yrs) to parent □ □ □
Grandparent to child □ □ □
Child (>18yrs) to grandparent □ □ □
Aunt/uncle to niece/nephew □ □ □
Niece/nephew to aunt/uncle □ □ □
Partner to partner □ □ □
Friend to friend □ □ □
Paired exchange (pending ULTRA) □ □ □
Altruistic (pending ULTRA) □ □ □
5. During the live donor assessment, which of these investigations is performed
as routine?
Fasting blood glucose
24hour urine for creatinine clearance

















6. Does your unit perform the live donor transplant procedure:
Simultaneously□ Sequentially □ Comment..
7. Do you offer laparoscopic donation if appropriate?
Yes □ Nod
Number of laparoscopic donor nephrectomies in 2001
8. Funding issues:
Does the health board for the recipient reimburse donor expenses?
Yes □ Nod Comment
Is there any other means of reimbursing donors?
Yes D Nod Comment
With the following scenarios, please complete responses after consultation and
general agreement with the multi-disciplinary team:
9. A 45 year old woman wishes to donate a kidney. She is married with 3 children
- age 9, 11 and 15 years old. Her corrected isotope GFR is 68 mls/min,
creatinine clearance 80mls/min and differential scan shows equal kidney
function. All other investigations are satisfactory. Please tick these two
scenarios:
She wishes to donate to her 15 year old son, who is pre-dialysis.
Would you proceed? Yes DNoD
She wishes to donate to her friend, whom she has known since schooldays. There
is no evidence of co-ercion, financial or otherwise:
Would you proceed? Yes DNoD
10. A 60 year old man wishes to donate to his 28 year old son. The donor has well
controlled hypertension on one anti-hypertensive agent. All investigations are
satisfactory other than the echocardiogram, which showed mild left ventricular
hypertrophy. He is fully aware of these results and determined to proceed.
Would you proceed? Yes DNo □
11. A 24 year old woman wishes to donate to her 55 year old diabetic father. There
are no other suitable family members, and her father has been on the transplant
list for five years. Recently the recipient has been having problems with vascular
access.
Would you proceed? Yes UNo □
Follow-up
12. Are donors offered long term follow-up? Yes DNo □
13. For what period of time? < 1 year D5 years □ 10 years □
LifeO Other




Independent Medical Assessor □
General practitioner D
Other




Urea & electrolytes □
Haemaglobin □
Glucose □





16. Who completed this questionnaire? Please tick all personnel involved
Transplant Co-ordinator/Nurse Practitioner □
Transplant Surgeon □
Transplant Nephrologist O
All of the above D
Other
Many thanks for completing this questionnaire
Please return to:
Jen Lumsdaine; Transplant Unit, Royal Infirmary of Edinburgh
(addressed envelope enclosed)
Estimation of creatinine clearance by formula
From the measured serum creatinine level (SCr) the creatinine clearance was estimated
using three different formulae:
According to the Cockcroft-Gault formula:
CClco - 0.85"* x (140-age) x weight x Hi x 88
72 x SCr BSA
The variable associated with the sex of a patient takes the value unity for a female and
zero for a male. The multiplier of 88 is used to convert the measured SCr value from
pmol/1 to mg/dl and age is in years.
The formula due to Jelliffe. A simple result gives:
CC1 j = 0.90sex x 98-°-8(age-20) x — x 88
SCr BSA
The more complicated expression from Jelliffe and Jelliffe gives:
_ Ecor 1.73 coCC1J2 = x x 88
14.4 x SCr BSA
where
1344-(43.76 x SCr))Ecor = Ess x —
1344- (43.76 x 1.1)
and
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Domain 1 (6-Q3) + (6-Q4) + Q10+ Q15 + Q16 + Q17 + Q18
□ + □ + □+ □ + □+ □+□ =
Domain 2 Q5+ Q6+ Q7 + Q11 + Q19 + (6-Q26)
□ + □+ □ + □+ □+ □ =
Domain 3 Q20 + Q21 +Q22
□ + □ + □ =
Domain 4 Q8+ Q9+ Q12+ Q13+ Q14 + Q23+Q24 + Q25
□ +□+□ + □+□+□+□+□ =
* Please see Table 4 on page 10 of the manual, for converting raw scores to transformed scores.
This document is not issued to the general public, and all rights are reserved by the World Health Organization (WHO). The
document may not be reviewed, abstracted, quoted, reproduced or translated, in part or in whole, without the prior written
permission of WHO. No part of this document may be stored in a retrieval system or transmitted in any form or by any means -
electronic, mechanical or other - without the prior written permission of WHO.
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ABOUT YOU
Before you begin we would like to ask you to answer a few general questions about yourself: by circling the correct
answer or by filling in the space provided.
What is your gender?














What is your marital status? Single
Married
Living as married
Are you currently ill? Yes No
If something is wrong with your health what do you think it is?_
Instructions
This assessment asks how you feel about your quality of life, health, or other areas of your life. Please answer all the
questions. If you are unsure about which response to give to a question, please choose the one that appears most
appropriate. This can often be your first response.
Please keep in mind your standards, hopes, pleasures and concerns. We ask that you think about your life in the last two
weeks. For example, thinking about the last two weeks, a question might ask:
Not at all Not much Moderately A great deal Completely
Do you get the kind of support from 1 2 3 4 5
others that you need?
You should circle the number that best fits how much support you got from others over the last two weeks. So you
would circle the number 4 if you got a great deal of support from others as follows.
Not at all Not much Moderately A great deal Completely
Do you get the kind of support from 1 2 3 4 5
others that you need?
You would circle number 1 if you did not get any of the support that you needed from others in the last two weeks.
MSA/MNH/PSF/97.6
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Please read each question, assess your feelings, and circle the number on the scale for each question














2 (G4) How satisfied are you with your health? 1 2 3 4 5
The following questions ask about how much you have experienced certain things in the last two weeks.
Not at all A little A moderate
amount
Very much An extreme
amount
3 (F1.4) To what extent do you feel that physical
pain prevents you from doing what you
need to do?
1 2 3 4 5
4(F11.3) How much do you need any medical
treatment to function in your daily life?
1 2 3 4 5
5(F4.1) How much do you enjoy life? 1 2 3 4 5
6(F24.2) To what extent do you feel your life to
be meaningful?
1 2 3 4 5
Not at all A little A moderate
amount
Very much Extremely
7(F5.3) How well are you able to concentrate? 1 2 3 4 5
8 (F 16.1) How safe do you feel in your daily life? 1 2 3 4 5
9 (F22.1) How healthy is your physical
environment?
1 2 3 4 5
The following questions ask about how completely you experience or were able to do certain things in the last two weeks.
Not at all A little Moderately Mostly Completely
10 (F2.1) Do you have enough energy for
everyday life?
1 2 3 4 5
11 (F7.1) Are you able to accept your bodily
appearance?
1 2 3 4 5
12 (F 18.1) Have you enough money to meet your
needs?
1 2 3 4 5
13 (F20.1) How available to you is the information
that you need in your day-to-day life?
1 2 3 4 5
14 (F21.1) To what extent do you have the
opportunity for leisure activities?
1 2 3 4 5





15 (F9.1) How well are you able to get around? 1 2 3 4 5









16 (F3.3) How satisfied are you with your sleep? 1 2 3 4 5
17 (F10.3) How satisfied are you with your ability
to perform your daily living activities?
1 2 3 4 5
18(F 12.4) How satisfied are you with your capacity
for work?
1 2 3 4 5
19 (F6.3) How satisfied are you with yourself? 1 2 3 4 5
20(F13.3) How satisfied are you with your personal
relationships?
1 2 3 4 5
21 (F15.3) How satisfied are you with your sex life? 1 2 3 4 5
22(F14.4) How satisfied are you with the support
you get from your friends?
1 2 3 4 5
23(F 17.3) How satisfied are you with the
conditions of your living place?
1 2 3 4 5
24(F19.3) How satisfied are you with your access
to health services?
1 2 3 4 5
25(F23.3) How satisfied are you with your
transport?
1 2 3 4 5
The following question refers to how often you have felt or experienced certain things in the last two weeks.
Never Seldom Quite often Very often Always
26 (F8.1) How often do you have negative feelings
such as blue mood, despair, anxiety,
depression?
1 2 3 4 5
Did someone help you to fill out this form?
How long did it take to fill this form out?
Do you have any comments about the assessment?
THANK YOU FOR YOUR HELP
ADDITIONAL QUESTIONS FOR THE DONOR - PRE OP
Please indicate on the scale provided where your views lie, by marking the line with a cross
ie:
Not An extreme
at ail I I amount
1. Has your relationship with the recipient improved following the issue of donation?
Not An extreme
at all I I amount
2. Has the issue of donation had an adverse affect on your relationship?
Not An extreme
at all I I amount
3. Has your relationship with other family members improved following the issue of
donation of a kidney?
Not An extreme
1 at all I I amount
4. Has the issue of donation had an adverse affect on your relationship with other family
members?
Not An extreme
at all I I amount
5. Have you concerns about the operation?
Not An extreme
at all I I amount
6. Have you concerns about the remaining kidney?
Not An extreme
at all I I amount
ADDITIONAL QUESTIONS FOR THE DONOR-POST OP
Please indicate on the scaleprovided where your views lie, by marking the line with a cross
ie:
Not . An extreme
at all I I amount
1. Has your relationship with the recipient improved following donation?
Not . An extreme
at all r~ I amount
2. Has donation had an adverse affect on your relationship?
Not An extreme
at all I I amount
3. Has your relationship with other family members improved following your donation
of a kidney?
Not
, , An extreme
at all I I amount
4. Has your donation ofa kidney had an adverse affect on your relationship with other family
members?
Not - An extreme
at all I I amount




















ADDITIONAL QUESTIONS FOR RECIPIENT- PRE AND POST OP
Please indicate on the scaleprovided where your views lie, by marking the line with a cross
ie:
Not . An extreme
at all I I amount
1. Has the issue ofkidney donation improved your relationship with the donor?
Not
, j An extreme
at all I 7 I amount
Has the issue ofa kidney donation had an adverse affect on your relationship with the
donor?
Plot , | An extreme
atall I I amount

















Estimation of creatinine clearance by formula
From the measured serum creatinine level (SCr) the creatinine clearance was estimated
using three different formulae:
According to the Cockcroft-Gaultformula:
CClcc = 0.85-x (""»-age)xweigl" X 1^x88
72 x SCr BSA
The variable associated with the sex of a patient takes the value unity for a female and
zero for a male. The multiplier of 88 is used to convert the measured SCr value from
pmol/1 to mg/dl and age is in years.
Theformula due to Jelliffe. A simple result gives:
CC1, = 0.90sex x 98-0.8(age-20) „ 1.73 „ gg
SCr BSA
The more complicated expression from Jelliffe and Jelliffe gives:
CC1J2 = x —— x 88
14.4 x SCr BSA
where
Ecor = Ess x 1344-(43.76 x SCr))
1344- (43.76 x 1.1)
and
Ess = 0:9sex x weight x 0.95 x (29.305 - 0.203age)
Appendix 7: Publications
1. Lumsdaine JA, Wigmore SJ, Forsythe JL. Live kidney donor assessment in the UK
and Ireland. Br JSurg 1999;86:877-81.
2. Lumsdaine JA, Wigmore SJ, Wooton D, Stewart C, Akyol M, Forsythe JL.
Establishing a transplant coordinator-led living kidney donor follow-up clinic.
Prog Transplant 2003;13:138-41.
3. Clarke S, Lumsdaine JA, Wigmore SJ, Akyol M, Forsythe JL. Insurance issues in
living kidney donation. Transplantation 2003;76:1008-9.
4. Lumsdaine JA, Wray A, Power MJ, Jamieson NV, Akyol M, Andrew Bradley J et
al. Higher quality of life in living donor kidney transplantation: prospective cohort
study. Transpl Int 2005;18:975-80.
191
Original article
Live kidney donor assessment in the UK and Ireland
J. A. Lumsdaine, S. J. Wigmore and J. L. R. Forsythe
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Background: The criteria and methods for assessing live kidney donors are not clear. This study was
undertaken to establish whether there is a consensus regarding the organization and methods of
assessment of living kidney donors by renal transplant centres in the UK and the Republic of Ireland.
Methods: All transplant centres in the UK and Ireland involved in living donor kidney transplantation
were contacted by telephone survey followed by postal questionnaire.
Results: Considerable variation was observed in the organization of living kidney donor evaluation and
the methods of assessment used. The upper and lower age limits considered acceptable for kidney
donation were variable, with six of 29 centres setting no lower age limit and 11 setting no upper age
limit. Four centres do not currently offer living donor kidney transplantation. Of the 29 centres involved
with living donor transplantation ten had no protocol for donor assessment. A dedicated transplant
coordinator/nurse practitioner was employed by 20 centres and ten routinely used an independent
medical assessor to evaluate living related donors. The frequency and duration of donor follow-up after
kidney donation also varied widely, with 18 centres providing life-time, seven limited and three no
follow-up after initial postoperative assessment.
Conclusion: The wide variation in organizational structure and method of assessment of living kidney
donors in the UK and Ireland supports the need for establishment of guidelines for this practice.
Paper accepted 10 March 1999 British Journal of Surgery 1999, 86, 877-881
Introduction
In the UK there was a 12 per cent reduction in the number of
cadaveric renal transplants performed between 1990 and
1996. During the same period the number of patients
waiting for kidney transplants increased by 48 per cent. The
King's Fund report1 in 1994 on the provision of donor
organs for transplantation recommended that living dona¬
tion should be expanded in an attempt to increase the
availability of kidneys for transplantation. Between 1990
and 1996 live kidney donor transplantation increased by 81
per cent but still accounted for only 10 per cent of all renal
transplants performed in 1996. This value is substantially
lower than that reported by other European countries, such
as Norway and Sweden where 39 and 27 per cent
respectively of all renal transplants performed between
1991 and 1995 were living donor operations2.
The benefits of live kidney donation for subsequent graft
survival are well known. The 10-year graft survival rate
estimate is 84 per cent for a human leucocyte antigen (HLA)
identical sibling graft and 80 per cent for a one-haplotype
identical graft, compared with 47 per cent for a cadaveric
transplant3. The graft survival of non-HLA-matched
unrelated grafts is also superior to cadaveric transplant¬
ation, with a 6-year survival rate of 78 per cent3. While the
benefits for the recipient are evident, surgical removal of a
kidney from a healthy donor is not without risk. Previous
studies have reported an operative mortality rate of 0-03-
0-06 per cent in live kidney donors4"6. Other risks include
postoperative complications, long-term impairment of
renal function, hypertension, psychological morbidity and
loss of time and income7. The potential benefits for the live
donor include an intensive medical investigation with
undiagnosed medical problems being identified and treated
plus the psychological benefit of organ donation7.
Live kidney donation is subject to legislation in the UK.
The Human Organ Transplant Act 1989 and associated
Regulations8 permit transplants from living related and
unrelated donors, forbid any form of payment, but allow
reimbursement of legitimate expenses to the donor. Where
the donor and recipient are blood relatives, genetic
confirmation is required. In other circumstances potential
live donation must be referred to the UK Unrelated Live
Transplant Regulatory Authority (ULTRA).
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It has been suggested that the evaluation of potential
live donors in the UK is often based on empirical rather
than clinical evidence9. The purpose of the present study
was to establish the organization, methods and criteria
currently used for live donor assessment in the UK and
Ireland.
Materials and methods
All 35 of the renal transplant centres in the UK and the
Republic of Ireland were contacted. A structured ques¬
tionnaire was sent to 31 centres which are involved in live
donor transplantation or assessment, as identified by
telephone survey. The questionnaire was designed to
establish factors relating to donor assessment, exclusion
criteria and follow-up. The centres identified a person
responsible for organization of live donor transplantation to
whom the questionnaire was sent.
Results
In the UK and Ireland 1503 cadaveric renal transplants and
165 live donor transplants were performed in 1997 by 35
transplant centres. Four centres do not perform living
donor transplantation and of the 31 centres sent a
questionnaire 29 responded. These centres had performed
1474 cadaveric renal transplants (98 per cent of the total for
the UK and Ireland) and 150 live donor transplants (91 per
cent of the total) of which nine were living unrelated
transplants performed in seven centres. The questionnaire
was completed by the transplant coordinator responsible
for living donor transplants alone in 17 centres, with a
transplant surgeon in four centres, with a renal physician in
six centres, by a transplant surgeon alone in one centre and
by a transplant surgeon and physician in one centre.
The organization of live donor assessment was examined.
It was established that 19 centres had an established
protocol, four were in the process of devising a protocol
and six had no protocol. The assessment of live donors was
led by a transplant surgeon in eight centres, renal physician
in ten, transplant coordinator in one, transplant coordinator
and renal physician in two, and in eight the responsible
person was not identified. A designated transplant coordi¬
nator/nurse practitioner was used by 20 centres to manage
live donor transplantation.
Donor and recipient were seen separately in all centres
and were also interviewed together in 25 of the centres.
Assessment by a psychiatrist or psychologist was routine for
live related donors in five centres and for unrelated donors
in six centres, and was a referral option in 13 centres for both
live related and unrelated donors.
Recipients were removed from the cadaveric transplant
waiting list when donor assessment was complete in four
centres, on the date of operation in 17 centres, after
discussion with recipient and donor in three centres and
four centres had no defined policy; there was one non-
respondent. Twenty centres did not have an agreed time
period between initial assessment and date of operation. A
period of 3 months was suggested by four centres and
6 months by five.
Investigations
Baseline investigations concerning the general fitness of the
donor included full blood count, serum urea, creatinine and
electrolyte estimation, liver function tests, chest radio¬
graphy, electrocardiography and urinalysis; these tests were
performed by all centres. Serum levels of calcium and
phosphate were measured in 28 centres, uric acid in 20,
thyroid function was determined in three, lipid profile in
two and erythrocyte sedimentation rate in one centre.
Investigations relating to diabetes, hypertension, infection
screening, renal function, renal tract anatomy and histo¬
compatibility are summarized in Table 1. Other investiga¬
tions reported were exercise tolerance test (four centres),
cervical smear for female donors (one) and bladder
ultrasonography for older male donors (one).
Hypertension
Defined values for hypertension as an exclusion
criterion had been established in 12 centres, but not
in the majority. Using the World Health Organization
criteria for hypertension (mild hypertension: systolic
pressure of 140-180 mmHg and/or diastolic pressure of
90-105 mmHg) and the example of an otherwise fit 40-
year-old man, nine centres would have excluded a
donor taking one antihypertensive drug and who had
no evidence of end-organ damage (no left ventricular
failure or microalbuminuria). Thirteen centres would
have excluded a donor with mild hypertension who was
taking no medication and who had no end-organ
damage. Twenty-one centres would have excluded a
donor with borderline hypertension with evidence of
end-organ damage, and nine would exclude such a
donor if end-organ damage were absent.
Creatinine clearance
Using the scenario of a 50-year-old woman weighing 60 kg,
levels of creatinine clearance below which exclusion from
kidney donation should occur were considered to be
llOml/min by two centres, lOOml/min by four, 90ml/
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Table 1 Summary of investigations performed as part of living
donor assessment




Random blood glucose 27
Fasting blood glucose 9
Blood pressure
Erect and supine blood pressure 23
Serial blood pressure 7










24-h urine for protein and 23
creatinine clearance
Isotope glomerular filtration rate 24
Renal tract anatomy
Angiography 28
Spiral computed tomography 1
Renal ultrasonography 23




Flow cytometric cross-match 21
min by four, 80 ml/min by seven and 70 ml/min by two. No
response to this question was received from ten centres.
Diabetes
A fasting blood glucose concentration of more than
6 mmol/l was considered an exclusion criterion for organ
donation by 15 centres, a relative contraindication by two
centres and not an exclusion criterion by ten; two centres
did not respond. A family history ofdiabetes was considered
an exclusion criterion by four centres but not by 23, it was
considered to be a relative contraindication by one centre
and one centre did not respond.
Obesity
There were no exclusion criteria for obesity in ten centres.
Others excluded donors whose body-weight exceeded their
ideal body-weight by 15-20 per cent (eight centres), by 10-
15 per cent (six centres) and by less than 10 per cent (three
centres). One centre defined a body mass index ofmore than
Table 2 Minimum and maximum ages of living kidney donors
considered by transplant centres in the UK and Ireland
No. of centres


















40 or weight greater than 100 kg as exclusion criteria, while
another excluded patients with a body mass index over 30.
Other exclusion criteria
A potential donorwith a history ofalcohol abuse would have
been excluded by 15 centres but considered by ten and four
did not respond. Smokers ofmore than 20 cigarettes per day
would have been excluded as organ donors by six centres but
considered by 20, three did not respond.
The exclusion criteria used by centres with respect to
minimum and maximum acceptable age for the donor are
illustrated in Table 2. Child to parent donation would be
considered in 25 centres, although most considered this
appropriate only in exceptional circumstances, and this
relationship would not have been considered in four
centres. Women of childbearing age were considered as
donors by all centres. Donors with mild learning disability
would be accepted as donors by 11 centres and excluded as
donors by a further 11. Seven centres either stated that
individual assessment would be required or did not answer
the question. Potential donors with moderate learning
disability were excluded by 20 centres but would be
accepted by three and six did not respond.
Donor follow-up
Follow-up for live kidney donors was organized by the
transplant unit in 28 centres and in 11 this care was
coordinated jointly with the donors' general practitioners.
One centre relied solely on the general practitioner for
follow-up of the donor. The duration of follow-up of
donors was reported as lifetime by 18 centres, 10 years by
one centre, 5 years by two and 1 year by four. Following
initial postoperative assessment no further follow-up was
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arranged by three centres, and there was one non-
respondent. One year after organ donation, donors were
seen every 6 months in one centre, annually by 19 centres
and biannually by one. In the event of an unsuccessful
transplant, counselling facilities were provided for the
donor by 15 centres but were not available in 12 centres; no
information was provided by two centres.
Discussion
This study surveyed the practice of live donor assessment by
centres in the UK and Ireland which were responsible for 98
per cent of cadaveric and 91 per cent of live donor kidney
transplants performed in 1997. Four centres do not perform
living donor transplantation and only seven performed a
living unrelated transplant in 1997. This raises the
possibility that patients in some centres may not have equal
access to the benefits of living related and living unrelated
transplantation. Those involved in purchasing renal
healthcare for a population might reasonably ask that this
modality of treatment be available to all willing and eligible
patients. In addition the investigation of a donor and the
definition of responsibility for that investigation would be
considered very important, yet at the present time ten of 2 9
centres involved in live donor transplantation do not have an
agreed protocol.
The assessment of live donors is variably led by renal
transplant surgeons and physicians, raising the question of
who should be responsible for this role. It could be argued
that the responsibility for the donor ultimately lies with the
surgeon and that there is a potential conflict of interest for
the renal physician, since it is the renal recipient who derives
clinical benefit from the procedure. All unrelated donors are
required to be seen by an independent medical assessor.
Although not a requirement under transplant legislation,
independent medical assessors were used by ten centres to
assess related donors. This perhaps reflects concern over the
best representation of the donor's interests and the need to
have a donor's advocate. All centres interview the donor
separately from the recipient, implying cognizance of the
importance of ascertaining the family dynamics9 and
providing an opportunity for donors to raise specific
concerns which they may not wish to share with recipients.
This raises the question of whether greater involvement of
psychologists would aid in clarification of these issues.
There are no data indicating the optimal time to remove
recipients from the cadaveric transplant waiting list once
live donor transplant has been agreed. The predicament
exists between the avoidance of surgery on a healthy
individual who will derive no clear direct benefit and the
improved graft survival rate following live donor transplan¬
tation in comparison with cadaveric transplantation. In
addition, a cadaveric organ which is not used because the
recipient is transplanted from a living donor source is then
used to benefit another patient on the waiting list who may
not have the option of living donor transplantation.
Coupled with this issue is the question of whether it is
useful to have a time lapse between initial donor assessment
and subsequent transplantation. When a policy of leaving
the recipient on the cadaveric transplant waiting list until
the date of live donor transplantation is pursued in tandem
with a long time lapse between donor assessment and
transplantation, this will inevitably reduce the availability of
cadaveric organs for transplantation since some recipients
will be offered cadaveric transplant in the interval. In the
present study the majority ofcentres did not identify a rigid
time period but there was a consensus that assessment
should not be hurried. Furthermore, there are individuals
who have varying degrees ofcommitment to donation and it
may be important to consider the views of the donor and
recipient before deciding on the most appropriate time for
removal of the recipient from the cadaveric transplant
waiting list.
General investigations were performed by all centres but
considerable variability was observed in the methods and
thoroughness of infection screening, assessment of renal
tract anatomy and renal function. No clear guidelines are
available, based on sound clinical evidence, to indicate
which factors should be considered as exclusion criteria for
live organ donation. This is reflected in the variability in
response to creatinine clearance as an exclusion criterion
and the relatively high rate (ten of 29 centres) of non-
responders to this question. The ethical dilemma of organ
donation and informed consent from donors with learning
difficulties is demonstrated by the low rate of acceptance
(three of 29) of donors with moderate learning disability in
the present study. In the USA, Bia et al.4 found that 46 per
cent of centres do not have a policy regarding the use of
donors with learning disabilities and 6 per cent accepted
donors with severe intellectual impairment.
A further ethical dilemma relating to live donor
transplantation arises with respect to the age of the donor.
In the UK, 16 years is the legal age for provision of
informed consent; however, in the present study six centres
set no minimum age for organ donation. The most common
age below which organ donation would not be considered
was 18 years. At the other end of the scale, older donors have
often been considered a greater operative risk and the
functional results of grafts derived from older cadaveric
donors are inferior to those from younger donors10. Data
from a large series of living donors suggest that graft survival
is also dependent on donor age". In the present study, 11
centres set no maximum age limit and a further six would
consider live donation from donors over 70 years of age. In
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spite of a move to include older donors, only 3 per cent ofall
living kidney donors reported by the United Network of
Organ Sharing were over 60 years of age12.
Child to parent donation would be considered in 2 5 of the
29 centres, and all would consider women of childbearing
age as potential donors. Buszta etal.1} demonstrated that
donor nephrectomy does not result in any increased risk of
hypertension or hyperfiltration damage associated with
subsequent pregnancy. Questions relating to the use of
borderline or mildly hypertensive donors revealed that the
most important consideration was the presence of end-
organ damage.
A recent study highlighted the concern that nephrectomy
may increase the subsequent risk of developing nephro¬
pathy and advocated thorough evaluation of potential
donors for diabetes and diabetic nephropathy14. In the
present study, however, ten centres did not consider a blood
glucose concentration greater than 6mmol/l to be an
exclusion criterion for kidney donation.
Considerable variation was evident in the duration and
frequency of follow-up of live donors. It is only relatively
recently that 20-year data have become available on live
kidney donors and, apart from the benefit of reassurance
offered by long-term follow-up, such information on the
live donor population would be of great value.
Currently live donor kidney transplantation is organized
in a single national centre in both Norway and Finland.
There are four centres involved in live donor transplanta¬
tion in Sweden, each of which has an individual protocol,
and research is currently in progress to establish the
differences between them (J. Wadstrom, personal commu¬
nication). Bia et al.* discussed the importance of examining
current practice patterns and defining issues that need
further study in their report on the practice of living donor
assessment in the USA. According to the United Organ
Sharing Network (personal communication) there is still no
national policy for living donor assessment in the USA. A
similar situation also exists in Australia, where there are no
national guidelines for living donor assessment. The British
Transplantation Society and the Renal Association have
established a working party to develop a national protocol
to provide a consistent standard of care and assessment of
live donors throughout the UK.
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Establishing a transplant coordinator-led
living kidney donor follow-up clinic
Background—The long-term risks of renal failure and hypertension are statisti¬
cally low for living kidney donors as a group, but can have serious consequences
for the individual.
Objectives—To describe the experience with a transplant coordinator-led living
donor follow-up clinic.
Method—Living kidney donors are reviewed on an annual basis by a designated
coordinator (registered nurse). A 24-hour urine collection estimates renal function.
Blood pressure and blood chemistry are measured and urinalysis performed.
Current health status and wound discomfort are assessed. Any medical problems
identified are referred to a specialist hospital department or to the donor's family
practitioner.
Results—Fifty-nine appointments were booked and 12 (20%) donors did not
attend. Renal function was within acceptable limits for all attending donors. Three
donors had raised blood glucose levels and 8 donors were hypertensive; all were
referred to family practitioners. Forty-seven donors (35 new, 12 return) completed
a questionnaire on the follow-up provided. Thirty-eight (81%) were satisfied with
the follow-up, and 47 (100%) agreed this clinic provided adequate follow-up.
Thirty-three (70%) donors stated they preferred that the transplant coordinator per¬
formed the follow-up, 3 (6%) preferred the family practitioner, and 11 (23%) had
no preference.
Conclusions—There are many possible solutions to the provision of lifelong care
of living kidney donors. The model of a transplant coordinator-led clinic appears
to have a high degree of patient acceptance, perhaps because of the continuity of
care provided by a known member of the transplant team. Further work is
required to identify reasons for nonattendance. (Progress in Transplantation.
2003;13:138-141)
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Living kidney donation is an increasingly commonmode of organ provision for kidney transplanta¬
tion because of the shortage of cadaveric organs and
increasing waiting lists. In certain European countries
such as Norway, the number of living kidney trans¬
plantations approaches the number of cadaveric trans¬
plantations.1 Although the reported risks of perioper¬
ative complications are low for living organ donors,
there is a lack of good quality prospective data exam¬
ining the long-term consequences of organ donation.
Some studies have shown that the long-term risks of
renal failure and hypertension are statistically low for
living kidney donors as a group,2 but can have seri¬
ous consequences for the individual. In a recent study,3
the investigators found that of 28 transplant centers
undertaking living donor transplantation in the
United Kingdom and the Republic of Ireland, 18
undertook lifelong follow-up, 7 arranged limited
follow-up, and 3 reported that they did not undertake
long-term follow-up. Similarly, in the United States,
only 13% of United Network for Organ Sharing-
approved centers recommend lifelong donor follow-
up.4 Part of the difficulty in recommending policy on
living kidney donor follow-up is that there are rela¬
tively few data on which to base such recommenda¬
tions. In a somewhat circular argument, the lack of
data lends weight to the call to establish a system of
long-term donor follow-up. The nature of follow-up
and who should undertake are also issues for debate.
With acknowledgment to the lack of literature concern¬
ing long-term follow-up, the British Transplantation
Society/Renal Association Guidelines for Living Kid¬
ney Donor Transplantation5 have advocated lifelong
follow-up.
The purpose of this article is to report the imple¬
mentation of a transplant coordinator-led living kidney
donor follow-up clinic and to explain the basis for its
establishment and agreed upon protocols.
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Background
During the assessment of potential living kidney
donors, the transplant team invests much time and effort
ensuring each potential donor is medically assessed and
fully informed of risks. Many believe that this duty of
care should persist after donation. A recent study exam¬
ining donors' perceptions of their health after kidney
donation included statements of concern about the lack
of contact with the transplant unit and nurse coordinator
following surgery.6 Specific problems exists, which liv¬
ing kidney donors may encounter, particularly in the
early postoperative period, that might not be obvious to
healthcare professionals who are not involved in dealing
with such patients on a regular basis. Therefore, the
transplant unit seems to be the ideal base on which to
center a clinic. The concept of establishing a follow-up
clinic for living kidney donors was 2fold: first, to ensure
that patients make a satisfactory recovery following
donation and, second, to obtain adequate information,
collected prospectively, of the long-term risks of kidney
donation for future potential donors.
The aims of the clinic included the following:
• To provide continuity of care by the transplant
team following donation
• To monitor renal function and blood pressure, as
well as ongoing medical status
• To provide a setting in which the long-term wel¬
fare of a cohort of living kidney donors could be studied
Implementation
Our clinic was designed to be led by a transplant
coordinator (qualified nurse) who has specific respon¬
sibility for living kidney donation and is actively
involved in the assessment of all living kidney donors.
Permission to implement the clinic was granted by the
hospital authorities, which funded the clinic on a trial
basis. In consultation with transplant surgeons and
physicians, protocols were developed following stan¬
dard guidelines for assessment and care in line with
other existing protocols within the hospital.
Terms of Reference
Any problems related to abnormal blood test
results, adverse events, or deterioration of renal func¬
tion are referred to a consultant physician for review
and further management. In addition, the nurse has
access for referral to the transplant surgeons and physi¬
cians who were involved with the donor periopera-
tively. Consequently, the clinic can be safely manned
by an experienced nurse who has security in the knowl¬
edge that there is a clear line of referral for senior med¬
ical advice should this be necessary.
Invitation to Attend Follow-Up
Since 1961, 150 living donor kidney transplanta¬
tions have been undertaken at our unit. When possi¬
ble, donors were traced and contacted initially by let¬
ter, inviting them to attend the clinic. All family prac¬
titioners were informed of the clinic and forthcoming
appointment. We were concerned that patients who
had donated a kidney some years before might worry
when receiving a letter inviting them to attend a clinic
after several years without follow-up. Therefore, the
purpose of the invitation and the implementation of
recent guidelines were quoted as reasons for estab¬
lishing the clinic. If no response was received and the
transplant recipient was known to the unit, the recipi¬
ent was consulted whether further approaches should
be made to initiate follow-up with the donor.
Clinic Organization
All kidney donors attend a transplant clinic 6
weeks after donation for review by a surgeon and
transplant coordinator. Thereafter, donors are sent an
annual appointment through the transplant coordina¬
tor clinic appointment system. Appointments are sched¬
uled at 30-minute intervals to leave sufficient time
for discussion. Donors are requested to commence a
urine collection 24 hours before attendance, and con¬
tainers for this purpose are mailed to them before
their attendance.
Clinical investigations are summarized in the
Table. Donors are asked specifically about problems
with wound pain, and general problems that may be
attributable to surgery. They are also given the oppor¬
tunity to ask any questions that they may have regard¬
ing their donation or general health.
Following the appointment, any abnormal clinical
results are discussed with an experienced physician.
The results are reported to the donor's family practi¬
tioner and the donor by letter and on occasion the
donor may be asked to reattend the clinic for further
assessment.
Clinic Audit
An audit was conducted to establish whether
patients were satisfied with arrangements for follow-
up and the structure of the clinic. Patients were asked







Hemoglobin and blood count
Creatinine clearance
Urinary protein quantification
the following questions to which they were requested
to respond yes or no:
1. Was it convenient for you to visit the hospital
today?
2. Was there enough flexibility with your
appointment date and time?
3. Did you feel that you received sufficient
follow-up after donating your kidney?
4. Do you feel that this living kidney donor clinic
will provide adequate follow-up?
In addition patients were given information that
the clinic is run by a transplant coordinator with a con¬
sultant (specialist doctor) reviewing the results.
Attendants were questioned whether they would pre¬
fer to be seen by the transplant coordinator with con¬
sultant review, a hospital doctor, or a family practi¬
tioner, or if they had no preference. Regarding the fre¬
quency of attendance for follow-up, attendants were
asked whether they felt annual review was too often,
not enough, or about right.
Results
Contact information was obtained for 47 living
donors who donated between the years 1986 and
2000. Fifty-nine appointments were booked (47 new;
12 return) and 12 new (20%) donors did not attend.
All the nonattendees were donors from the previous
living donor program, who were not aware of the
follow-up program.
Creatinine clearance, serum creatinine, and urea
were within acceptable limits for all donors (n = 35).
Three donors had raised blood glucose levels, 8.1
mmol/L, 8.6 mmol/L, and 9.5 mmol/L, respectively
(normal range 3.6-5.8 mmol/L), and were referred to
their family practitioners for further management.
Four donors had trace protein on dipstick urinalysis;
however, laboratory measurements were undetectable.
One donor was attending surgical clinic for ongoing
wound problems and 2 additional donors were referred
to the surgeons for review. Eight donors were found
to be hypertensive at the clinic visit (170/90 mm Hg
and 160/105 mm Hg), and all were referred to fam¬
ily practitioners. Two donors were taking antihyper¬
tensive agents.
Forty-seven audit questionnaires, which asked
about donors' views on the follow-up provided, were
completed (35 new; 12 return). Forty-three (91%)
donors stated it was convenient to visit the hospital,
forty-six (98%) felt there was enough flexibility
with the appointment, and 47 (100%) agreed it
would provide adequate follow-up. Thirty-eight
(81%) were satisfied with the follow-up they had
received after kidney donation. When asked their
preference with regard to who should undertake
their follow-up, 33 (70%) donors preferred a transplant
coordinator with consultant medical review, 3 (6%)
preferred a family practitioner, and 11 (23%) stated
that they had no preference (see Figure). Forty-two
donors (89%) felt an annual review was sufficient,
with the remaining 5 (11%) stating that it was not
frequent enough. If the donor found difficulty in
attending the clinic because of the geographic dis¬
tance, the local transplant unit or family practitioner
was contacted and arrangements were made for
donor follow-up using our model. In these circum¬
stances, the results of investigations were sent to our
unit for review.
Discussion
It is generally acknowledged that living kidney
donation makes an important contribution to the prob¬
lem of the international shortage of cadaveric organs.
The success of a living donor program is dependent on
low morbidity and mortality rates in the donors. The
principal focus of living donor care has been on the
assessment and perioperative care of the donor. A
similar emphasis must also be placed on the long-term
outlook of these individuals. Many centers in the
United Kingdom, and other countries, do not have a
structure for the follow-up of living donors. Part of the
reason for this is that there is little evidence upon
which to base recommendations for follow-up. Follow¬
ing guidelines that living donors should undergo life¬
long follow-up, we have initiated a clinic for the sole
purpose of living kidney donor follow-up.
The high attendance rate suggests that kidney
donors value the provision of long-term follow-up,
with acknowledgment of ongoing care from the trans¬
plant team. The preliminary audit results confirm
acceptability of a nurse-managed service. In addition,
attendees commented that they appreciated the flexi¬
bility of our appointment system. It is essential that
donors who live outside reasonable traveling distance
to the transplant unit receive similar care to those
attending the central unit; therefore, we have estab¬
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practitioners or district transplant units. Because many
transplant centers aim to increase the number of living
kidney donors, adequate resources should be made
for follow-up. In addition, living donor follow-up
clinics will enable improved quality of data that may
be used to provide more accurate information for
future living donors.
The referral pattern for ongoing surgical wound
pain, raised blood glucose levels, and high blood pres¬
sure readings confirms a need for continual monitor¬
ing. Early detection may prevent long-term damage to
the remaining kidney, and with minimally invasive
testing this can be achieved.
The model for living donation presented here may
not suit all centers, particularly those in which the
geographic distance of the donors precludes their
attendance at a central unit. We hope that the principles
that we have established will provide a useful model for
other centers wishing to establish similar clinics.
References
1. Select Committee of Experts on the Organisational Aspects •
of Cooperation in Organ and Tissue Transplantation.
International figures on organ donation and transplantation
activities 1998. Organs Tissues. 1999;1:73-78.
2. Najarian J, Chavers B, Muhugh L, Matas J. 20 Years or more of
follow up of living kidney donors. Lancet. 1992;340:807-810.
3. Lumsdaine JA, Wigmore SJ, Forsythe JLR. Live kidney donor
assessment in the UK and Ireland. Br J Surg. 1999;86:877-881.
4. Bia MJ, Ramos EL, Donovitch GM, et al. Evaluation of liv¬
ing renal donors. The current practice of US transplant cen¬
ters. Transplantation. 1995;60:322-327.
5. British Transplantation Society and British Renal
Association. United Kingdom Guidelines for Living Donor
Kidney Transplantation. 2000. Available at: http://www.bts
.org.uk/Forms/LDKTGuides/pdf. Accessed April 4, 2003.
6. De Graaf Olson W, Bogetti-Dumlao A. Living donors'per¬
ception of their quality of health after donation. Prog
Transplant. 2001; 11:108-115.
Progress in Transplantation, Vol 13, No. 2, June 2003 141
1008 TRANSPLANTATION Vol. 76, No. 6
solely to monitor the infusion process, but also because they
need intensive monitoring and surveillance and have a high
risk of developing an infection if treated on an outpatient
basis. One would be interested in knowing how these pa¬
tients fared in the long term and whether they experienced
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TRANSPLANTATION
I appreciate the comments of Mr. Mahawar. As he correctly
states, the manufacturers of Thymoglobulin (SangStat Medical
Corporation, Fremont, CA) suggest only the use of a "high flow
vein" and not specifically a central vein for the administration of
Thymoglobulin. However, many published studies clearly indi¬
cate its administration through a central line (1,2). I also agree
with the author that many other centers are currently admin¬
istering Thymoglobulin through peripheral access. The purpose
of publishing this article was to more broadly endorse the prac¬
tice of peripheral administration.
Although no formal statistical analysis was performed in
regard to postadministration infection, no difference was
noted in our ambulatory versus hospitalized patients.
Michael R. Marvin
Address correspondence to Michael R. Marvin, M.D., 19 Bradhurst
Avenue, Suite 3150, Hawthorne, NY 10532. E-mail: marvinm®
wcmc.com.
Received 14 May 2003. Accepted 15 May 2003.
REFERENCES
1. Brennan, DC, Flavin, K, Lowell, JA, et al. A randomized, double-blinded
comparison of Thymoglobulin versus Atgam for induction immunosup¬
pressive therapy in adult renal transplant recipients. Transplantation
1999; 67: 1011.
2. Ormrod D, Jarvis B. Antithymocytc globulin (rabbit). A review of the use of
Thymoglobulin in the prevention and treatment of acute renal allograft
rejection. BioDrugs 2000; 14: 255.
DOI: 10.1097/01.TP.0000082560.75406.A6
INSURANCE ISSUES IN LIVING KIDNEY DONATION
We have undertaken a study to ascertain the perspective
of U.K. insurance companies to provision of insurance to
living kidney donors. WHICH (consumer guide) and cus¬
tomer directories were used to identify the major life and
health insurance providers in the United Kingdom, who
were then invited to complete specific questionnaires.
The results were as follows: 14 life insurance companies,
insuring approximately 6.5 million customers (79% of U.K.
life insurance market), replied. When questioned regard¬
ing their policy if an existing customer should die during
kidney donation, 13 of 14 stated that they would pay the
agreed life insurance sum. One company did not provide an
answer, as they had no experience of the situation and are
currently deciding their position for future reference. No
companies required to be informed by a customer of their
intention to donate. Furthermore, all would accept new
customers after previous kidney donation and would not
charge an increased premium but indicated that time con¬
siderations since donation were a factor in assessing such
customers (Table 1).
Regarding health insurance provision, seven major
health insurance companies replied; however, one did not
complete the questionnaire because they do not market
new business. Of the remaining six companies, half cover
existing customers for kidney donation. Should an existing
customer require a transplant, one company would pay
recipient medical expenses and would also pay donor costs
if the recipient and donor were both policy holders. All
companies accept new customers after previous kidney
donation, although two of six stipulate that they exclude
any problems arising from donation. Two of six charge an
increased rate and four of six do not. Time since donation
is considered to be relevant for new customers, as shown in
Table 1.
Insurance companies providing life insurance to almost
Table 1. Time since living kidney donation for new
customers considered relevant by life and health insurers
in the United Kingdom
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80% of the life insurance policy holders in the United
Kingdom would honor the terms of their agreement should
a customer die as a consequence of live kidney donation.
Premiums are not raised; therefore, kidney donation has
no long-term financial implications regarding life insur¬
ance. When considering new customers applying for insur¬
ance, there were significant inconsistencies among both
life and health insurers in the amount of time postdonation
that respondents considered relevant. Deaths associated
with live kidney donation are rare but occur predomi¬
nantly in the perioperative period, as do the great majority
of complications (1, 2), and so these time considerations
could be considered to be without scientific foundation.
It has been postulated thf t the increased life expectancy in
donor populations may be attributed to exclusion of concom¬
itant illness by the rigorous assessment (3-5). Considering
this, the reluctance of certain health insurers to provide
medical expenses for donors or sickness benefit is disappoint¬
ing. Equally, it could be argued that life insurance premiums
should actually be reduced postdonation. Kidney donation
may have financial implications for health insurance; how¬
ever, the long-term effects of this are minimized because of
the current structure of the National Health Service in the
United Kingdom. The inconsistencies in many aspects of
insurance provision to live kidney donors highlight the ne¬
cessity to share information and strive for evidence-based
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Summary
This prospective, longitudinal cohort study investigated the effect of donating
or receiving a kidney on quality of life and relationship dynamics. Forty donors
and 35 recipients from two UK transplantation centres completed the World
Health Organisation quality of life questionnaire (WHOQOL) with additional
questionnaires before, 6 weeks and one year after operation. Before donation
the donor mean quality of life score in the physical domain was 18.8. This was
significantly higher than the UK value for a healthy person of 16.4 (P < 0.001).
Six weeks after operation, donor score reduced to UK normative levels however
improved again at one year (17.7). Recipient mean physical domain score
before was 11.4, significantly lower than the UK norm (P < 0.01), increasing to
16.0 one year after. Both donor (P < 0.009) and recipient (P < 0.05) experi¬
enced a significant improvement in their mutual relationship. Recipients
expressed anxiety about the donor before operation. Donors were not con¬
cerned about living with one kidney. We concluded that living kidney donation
has no detrimental effect on the physical or psychological well being of donors
one year after donation. Transplantation results in a major improvement in
quality of life for the recipient. Most donors would donate again, if this were
possible.
ntroduction
or many patients with end-stage renal failure, a living
onor kidney transplant offers the optimum treatment
nd can avoid the need for dialysis. The short- and long-
:rm clinical benefits to the recipient, of a planned opera-
Ion from a healthy donor with a brief cold ischaemic
me are well documented and result in a superior graft
urvival compared with cadaveric kidney transplants
1-3]. The clinical benefits for the donor are less clear,
luring the donor assessment period previously undetec-
:d health problems may be identified and treated [4]
nd those who are deemed suitable donors enjoy reassur-
nce concerning their health status [5].
Many previous studies examining quality of life issues
in living donor kidney transplantation have been retro¬
spective, or have focused on cohorts of either donors or
recipients in isolation. In the US, one study revealed that
live-kidney donors have similar or higher scores in all
quality of life domains compared with the healthy US
population and this observation was independent of the
time since donation [6]. Another European study demon¬
strated that recipients of both living donor and cadaveric
transplants had mean quality of life scores within one
standard deviation (SD) of the norm for healthy individ¬
uals [7]. Although such studies are useful, there is a lack
of objective longitudinal data examining the relationship
dynamics and quality of life of both donor and recipient
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as a pair through the process of living kidney donation
and transplantation.
The definition of quality of life is much debated. The
World Health Organization quality of life group (WHO-
QOL) describe 'an individual's perceptions of their posi¬
tion in life in the context of the culture and value
systems in which they live and in relation to their goals,
expectations, standards and concerns' [8]. One of the key
points in assessment of quality of life is the individual's
perception. The 'disability paradox' has been demonstra¬
ted in some studies that have shown that patients with
serious and persistent disabilities score their quality of life
higher than many external observers would anticipate [9].
This theory may be tested in the unique field of trans¬
plantation when a person with a chronic illness receives
an intervention that improves physical disability and
allows freedom from dialysis.
Relationships between donor, recipient and other fam¬
ily members provide a complex challenge. Feelings of
guilt have more prominence in the recipients of trans¬
plants originating from living donors compared with
cadaveric donors [7], Individuals donating a kidney were
less likely to say they would donate again (if it were poss¬
ible) if they were donating to a person who was not a
close blood relative or if the recipient of their kidney had
died in the first year after transplantation [6]. Qualitative
studies investigate complex relationships further, however,
again many are retrospective and baseline findings may
be difficult to compare.
The lack of good quality and objective data concerning
quality of life outcomes for living kidney donors and
transplant recipients means that it is difficult for health
care professionals to provide advice to individuals consid¬
ering kidney donation other than in the context of clin¬
ical measures such as graft survival and operative risk.
The present study was designed specifically to investigate
the effect of donating or receiving a kidney between
donor and recipient pairings on their quality of life and
relationship dynamics over time.
Methods
This prospective, longitudinal study was undertaken
between January 2000 and January 2004 in the transplant
units of the Royal Infirmary, Edinburgh and Adden-
broke's Hospital, Cambridge. Both centres had similar
policies regarding donor and recipient selection, preoper¬
ative assessment and perioperative care. During the
course of the study all donor nephrectomies were per¬
formed using an open technique with or without resec¬
tion of the 12th rib. Only adult subjects (>18 years) were
invited to participate as agreed with the local ethical
approval committees. Both donor and recipient were
asked to complete two questionnaires each at three time
points: before; 6 weeks after and 1 year after the live-
donor transplant. The questionnaires included the WHO-
QOL Bref and an additional questionnaire examining
relationship issues and concerns related to the procedure.
The WHOQOL Bref is a shortened form of the WHO-
QOL 100 and discriminates between 'well' and 'ill' sub¬
jects [8]. This was felt to be particularly important as
many quality of life questionnaires are designed to assess
the impact of illness on a population. As this study com¬
pared 'health/ donors and patients with end-stage renal
failure the WHOQOL Bref was selected. Data were also
available to compare an age-matched well population in
the UK. Twenty-six questions produce scores for four
domains; physical, psychological, social and environmen¬
tal, related to quality of life. The data were transformed
and analysed with SPSS, using Mann-Witney or Kruskal-
Wallis H test as appropriate (SPSS, Chicago, IL, USA).
Data are presented as boxplots. Additional questionnaires
were designed using a 10 cm linear-analogue scale with a
member of the WHOQOL group (MJP) assisting in the
development of the questions. The respondents were
asked to state their response from minimum to maximum
views on the scale. The recipients completed the same
questionnaire at the same time points. The donor pre and
postoperative questionnaire differed to encompass further
social and economic issues experienced post-donation.
The donor and recipient pairs were asked to complete
the questionnaire separately, to avoid conflict of
responses. The majority were completed during routine
clinic visits, although due to geographical limitations a
number was posted and returned. The questionnaires
were numerically coded and anonymous, although demo¬
graphic details were requested.
Results
Patient inclusion and characteristics
From January 2000 to December 2002 fifty-two donor
and recipient pairs consented to participate, three pairs
declined. Twenty-three of the pairs were parent to adult
child, 11 siblings, 16 spousal and 2 other nonrelated.
Forty donors and 35 recipients completed the question¬
naires at all three-time points. Individuals who did not
complete questionnaires at all time points were excluded
from analysis. Treatment for renal failure for the 35 recip¬
ients included 13 undergoing haemodialysis; 14 peritoneal
dialysis and 8 were transplanted before renal replacement
was necessary. All donors underwent open nephrectomy
in this selected group. The mean age of the donor was
49 years (range 24-71 years), the recipient's mean age
37 years (range 19-54 years). Twenty-five donors were
female and 15 donors male, 17 recipients were female and
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discussion
rhe goal of healthcare today is to improve the quality of
ife of patients, in addition to curing physical illness
10]. In 1946, the World Health Organization defined
lealth as 'a state of complete physical, mental and social
veil being and not merely the absence of disease and
nfirmity' [11]. We have shown that removing a healthy
)rgan from an individual causes short-term infirmity,
rhis prospective, longitudinal study has demonstrated
hat living donor kidney transplantation does not
idversely affect the longer term physical, psychological
tnd social well-being of donors and substantially
mproves many aspects of the lives of recipients. The
ntense medical evaluation of potential living kidney
donors results in the selection of only healthy, motivated
ndividuals. In addition, all live-kidney donors are
jncouraged to achieve a level of fitness prior to dona-
ion. In the light of this it is perhaps not surprising that
he physical domain score for donors before operation is
tbove the national norm, confirming results of previous
studies [12]. Likewise for the recipient, the physical
mprovement following transplantation confirms the
nenefit of this form of treatment.
The donors achieve a higher than normal psychological
score predonation, decreasing at 6 weeks and 1 year,
ilthough remain at a level above the healthy population.
It is possible that the selection of motivated individuals,
:oupled with the reassurance afforded by completion of
he assessment process and the knowledge that the donor
is fit to precede, improves psychological well being before
donation. Similarly, for the recipient the knowledge that a
:ransplant is imminent may increase a sense of psycholo¬
gical well being, in spite of the observed concerns that the
recipient has for the safety of the donor.
No significant change in the social and environmental
domain scores of either donor or recipient was observed,
rhis is reassuring information for future donors that no
idverse effect is caused by donation. It was anticipated
hat for the recipient, freedom from dialysis might have
esulted in improved social and environmental interac-
ion. The lack of change may reflect the fact that a num-
>er of transplants were 'pre-emptive', that is undertaken
>efore dialysis was instituted or the intensity of the fol-
ow-up after transplantation. Benefits in social and envi-
onmental domains may become more apparent in the
onger term, when the recipient does not require such
ntense follow-up.
Both the donor and recipient are informed in detail
ibout the risks and benefits of living donor transplanta-
ion [13], with great emphasis on the risks to the donor
indergoing a major operation. Thus recipient concerns
bout the donor are high before surgery, decreasing in
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response to successful outcome and donor recovery. The
donors continue to have a low level of concern about liv¬
ing with a solitary kidney. The emphasis during assess-.
ment that donation will only proceed with minimum risk
to the donor and maximum benefit to the recipient [12]
may partly reassure donors, alongside the life-long follow-
up commitment of the transplant team.
The impact of living kidney donation does not appear
to have adverse effects on relationships either between
donor and recipient or with other family members. The
rigorous evaluation process may preclude pairs with the
potential for family conflict. Donors consider that the act
of donation improves relationships with the recipient and
to a lesser extent with family and friends, whose support
is vital in the postoperative period.
This study has demonstrated that living donor kidney
transplantation does not adversely affect the lives of
donors and substantially improves many aspects of the
lives of recipients. Careful donor selection allows those
with a higher than normal physical quality of life to
donate without impairing their physical or psychological
status. As a group, the issue of donation and transplanta¬
tion does not have an adverse effect on relationships, fur¬
ther work will analyse individual effect. The majority of
living donors would donate again, providing reassuring
information for potential donors.
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Table 2. World Health Organization
quality of life group psychological, social
and environmental domain scores for
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Pre 6 weeks 1 year
n/s
Pre 6 weeks 1 year
P< 0.004
Figure 3 Changes in relationships between donor and recipient
before and after living donor kidney transplantation. Donors (a) and
recipients (b) both reported significant improvement in their relation¬
ships with each other following kidney donation and transplantation,
respectively.
Relationship and social issues
The impact of the issue of live-kidney donation on the
relationship of the pairing and family member and
friends was addressed. The participants were asked to
score on a linear analogue scale if the issue of live-kidney
donation had improved their relationship. The scale
measured 10 cm (0: not at all - 10: extreme amount).
The donor and recipient were also asked if the issue of
live-kidney donation had an adverse effect on relationship
using the same scale. Both donor and recipient experi¬
enced a significant improvement in their mutual relation¬
ship (Fig. 3). When asked if the issue of live-kidney
donation had any adverse effect on their relationship, the
donor mean score was 0.8 (predonation), 1.7 (6 weeks
post) and 2.2 (1 year post). The recipient mean score was
lower: 0.6 (pretransplant), 0.6 (6 weeks after) and 0.7
(1 year later).
The recipients were asked to score their level of con¬
cern about the donor on the same 10 cm scale (Fig. 4).
Figure 4 Recipients' concerns about the welfare of the donor before
and after living donor kidney transplantation.





Pre 6 weeks 1 year
n/s
Figure 5 Level of concern of donors over their remaining kidney
before and after living kidney donation.
Initially the recipients expressed a high level of concern
(mean score 8.8) reducing at 6 week to 5.4. The donor
was asked about their level of concern about their
remaining kidney (Fig. 5). Consistently the donors did
not worry about their remaining kidney - 0.8 (before the
operation and 6 weeks after) and increasing to 1.0 (1 year
after). Postoperatively, when asked about scar discomfort
experienced the mean donor score was 2.0 at 6 weeks and
2.4 at 1 year. When asked, if it were possible, would they
donate a kidney again, the donor mean score was 8.9 at
6 weeks and 9.3 at 1 year.
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Before 6 weeks after 1 year after
Donor physical quality of life domain
Figure 1 World Health Organization quality of life group physical
domain scores for adult donors of kidneys before, 6 weeks and 1 year
after kidney donation. The broken line represents the median physical
domain score in an age- and sex-matched healthy UK population.
There was a significant reduction in physical domain scores 6 weeks
after donation (%2 = 17.2; d.f. — 2; P < 0.0001 Kruskal-Wallis H test)
with scores returning to predonation levels by 1 year.
W'
UK well
Before 6 weeks after 1 year after
Recipient physical quality of life domain
Figure 2 World Health Organization quality of life group physical
domain scores for recipients of living donor kidney transplants before,
6 weeks and 1 year transplantation. The broken line represents the
median physical domain score in an age- and sex-matched healthy UK
population. Living donor kidney transplantation resulted in a signifi¬
cant increase in physical domain scores (*2=26.6; d.f. =2; P < 0.0001
Kruskal-Wallis H test).
18 male. One recipient died within 1 year of transplant
and one recipient received two live-donor transplants
over the time period, the first having failed within 1 year.
No donor suffered a major perioperative complication.
Quality of life assessment
The WHOQOL scores are reported in the four domains -
physical, psychological, social and environmental. The
mean physical scores for donors are summarized in Fig. 1
and further domain scores in Table 1. Recipients mean
physical score are demonstrated in Fig. 2 and further
domain scores in Table 2.
Within the physical domain the mean score for the
donor was significantly higher than the UK normative
value for a healthy person (P < 0.001). Six-week after
donation, the physical domain scores of donors reduced
to normative levels however improved again at 1 year,
although did not reach predonation levels. By contrast
the mean score for the recipient before transplantation
was significantly lower than the UK normative value for a
well person (11.4 pretransplant vs. 16.4 UK norm
P < 0.01). The physical domain quality of life measure¬
ment for the recipient significantly improved by 6 weeks
and continued to improve such that by 1 year following
living kidney transplantation it was not significantly dif¬
ferent from the UK normative value for a well person.
Donor psychological domain scores before kidney
donation were significantly greater than UK normative
values for a well person (P < 0.012). Although the donor
psychological domain mean decreased 6 weeks postdona-
tion, this score remained significantly higher than the UK
population normative value (P < 0.001). The recipient
psychological domain scores before transplant were not
significandy different from the UK normative value.
However, following transplantation the psychological
domain scores increased such that they were significantly
higher than UK normative values at 6 weeks and 1 year
(P < 0.01). There was no significant difference between
the donor and recipient psychological domain scores
1 year after kidney donation or transplantation, respec¬
tively.
There were no significant changes in either the
social or environmental domain scores of the donor or
recipient groups before and after kidney donation or
transplantation.
Table 1. World Health Organization
quality of life group psychological, social
and environmental domain scores for
adult donors of kidneys used for living
donor kidney transplantation.
Before 6 weeks 1 year UK well (n = 245)
Psychological 16.7-(16.0-8.0) 16.0(14.7-6.7) 16.0(14.0-7.2) 14.6 (12.0-7.5)
Social 17.3 (9.3-0.0) 17.3 (10.6-0.0) 17.3 (6.7-0.0) 15.4 (11.7-8.0)
Environmental 17.0 (12.0-0.0) 16.5 (9.00-0.0) 16.0(11.0-0.0) 14.7 (11.4-6.7)
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